Egfr - epidermal growth factor receptor Gene
Also Known as Wa5; wa2; Erbb; Errp; wa-2; Errb1; 9030024J15Rik
Species: Mus musculus
About Egfr
This gene has 5 transcripts (splice variants), 283 orthologues, 53 paralogues and is associated with 180 phenotypes. Broad expression in liver adult (RPKM 26.7), liver E18 (RPKM 8.7) and 15 other tissues.
Summary
Enables epidermal growth factor binding activity and epidermal growth factor-activated receptor activity. Involved in cellular response to amino acid stimulus and positive regulation of fibroblast proliferation. Acts upstream of or within several processes, including animal organ development; epidermal growth factor receptor signaling pathway; and protein autophosphorylation. Located in several cellular components, including basolateral plasma membrane; endocytic vesicle; and perinuclear region of cytoplasm. Is expressed in several structures, including alimentary system; brain; integumental system; limb; and respiratory system. Used to study Coronavirus infectious disease and aortic valve disease. Human ortholog(s) of this gene implicated in several diseases, including colorectal cancer; lung non-small cell carcinoma (multiple); pancreatic cancer; prostate cancer; and pulmonary Tuberculosis. Orthologous to human EGFR (epidermal growth factor receptor). [provided by Alliance of Genome Resources, Apr 2022]
Egfr Products (2)
| mRNA | Protein | Name |
|---|---|---|
| NM_207655.2 | NP_997538.1 | epidermal growth factor receptor isoform 1 precursor |
| NM_007912.4 | NP_031938.1 | epidermal growth factor receptor isoform 2 precursor |
Gene Ontology
- Molecular Function
- Biological Process
- Cellular Component
| Cellular Component GO Annotation | Evidence | Références | Source |
|---|---|---|---|
| located in basolateral plasma membrane |
IDA
IDA: Inferred from direct assay
|
7723235 | MGI |
| located in cell surface |
IDA
IDA: Inferred from direct assay
|
23918928 | MGI |
| located in endocytic vesicle |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in intracellular anatomical structure |
IDA
IDA: Inferred from direct assay
|
10534613 | MGI |
| located in nucleus |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| located in perinuclear region of cytoplasm |
IDA
IDA: Inferred from direct assay
|
20208556 | MGI |
| is active in plasma membrane |
IDA
IDA: Inferred from direct assay
|
6248866 | MGI |
| located in plasma membrane |
IDA
IDA: Inferred from direct assay
|
7641815 | MGI |
| is active in plasma membrane |
IGI
IGI: Inferred from genetic interaction
|
28783046 | MGI |
Egfr Protein Structure
Recep_L_domain: pfam01030 (56 - 167)
Furin-like: pfam00757 (183 - 334)
Recep_L_domain: pfam01030 (361 - 480)
GF_recep_IV: pfam14843 (504 - 635)
TM_ErbB1: cd12093 (633 - 678)
PTKc_EGFR: cd05108 (705 - 1017)
- 0
- 200
- 400
- 600
- 800
- 1000
- 1210 a.a.
| Protein Preferred Names | Protein Names | |
|---|---|---|
|
epidermal growth factor receptor |
|
Recombinant Egfr Proteins
| Cat. No. | Nom du produit | Accession | Pureté |
|---|---|---|---|
| HY-P72988 | EGFR Protein, Mouse (HEK293, Fc) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
| HY-P72989 | EGFR Protein, Mouse (HEK293, His, solution) | Q01279 (L25-S647) | ≥ 95%, as determined by reducing SDS-PAGE. |
Related Agents
- Approval
- Clinical Phase
- Pre-clinical Phase
Approval
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-15772 | Osimertinib | Inhibitor | 99.96% | Yes |
| HY-P9907 | Trastuzumab | Inhibitor | 99.80% | Unkown |
| HY-P9905 | Cetuximab | Inhibitor | 99.81% | Unkown |
| HY-50895 | Gefitinib | Inhibitor | 99.99% | Yes |
| HY-138298A | Trastuzumab deruxtecan | Inhibitor | 99.89% | Unkown |
| HY-50896 | Erlotinib | Inhibitor | 99.99% | Yes |
| HY-10261 | Afatinib | Inhibitor | 99.92% | Yes |
| HY-138298 | Trastuzumab deruxtecan (solution) | Inhibitor | 99.40% | Unkown |
| HY-50898 | Lapatinib | Inhibitor | 99.83% | Yes |
| HY-16069 | Tucatinib | Inhibitor | 99.82% | Yes |
| HY-P9921 | Trastuzumab emtansine | Inhibitor | 99.74% | Unkown |
| HY-32721 | Neratinib | Inhibitor | 99.93% | Yes |
| HY-P9985 | Disitamab vedotin | Inhibitor | 99.06% | Unkown |
| HY-13272 | Dacomitinib | Inhibitor | 99.74% | Yes |
| HY-15772A | Osimertinib mesylate | Inhibitor | 99.97% | Yes |
| HY-109061 | Lazertinib | Inhibitor | 99.87% | Unkown |
| HY-P9921A | Trastuzumab emtansine (solution) | 98.27% | Unkown | |
| HY-12008 | Erlotinib Hydrochloride | Inhibitor | 99.94% | Yes |
| HY-10261A | Afatinib dimaleate | Inhibitor | 99.74% | Yes |
| HY-112870 | Firmonertinib | Inhibitor | 99.89% | Unkown |
| HY-112823 | Almonertinib | Inhibitor | 99.83% | Unkown |
| HY-50895A | Gefitinib hydrochloride | Inhibitor | 99.85% | Yes |
| HY-104065 | Pyrotinib | Inhibitor | 98.84% | Unkown |
| HY-132842 | Sunvozertinib | Inhibitor | 99.62% | Unkown |
| HY-N0281 | Daphnetin | Inhibitor | 99.77% | Unkown |
| HY-135815 | Mobocertinib | Inhibitor | 99.04% | Yes |
| HY-15164A | Icotinib | Inhibitor | 99.96% | Yes |
| HY-79077 | Osimertinib dimesylate | Inhibitor | 99.96% | Yes |
| HY-32721B | Neratinib maleate | Inhibitor | 99.74% | Yes |
| HY-164718 | Sevabertinib | Inhibitor | 99.90% | Unkown |
| HY-50898A | Lapatinib ditosylate | Inhibitor | 99.96% | Yes |
| HY-19730 | Olmutinib | Inhibitor | 99.88% | Unkown |
| HY-112870A | Firmonertinib mesylate | Inhibitor | 99.97% | Unkown |
| HY-15772R | Osimertinib (Standard) | Inhibitor | 99.69% | Unkown |
| HY-50898B | Lapatinib ditosylate monohydrate | Inhibitor | 99.99% | Yes |
| HY-104065B | Pyrotinib dimaleate | Inhibitor | 98.04% | Unkown |
| HY-112823B | Almonertinib hydrochloride | Inhibitor | 98.92% | Unkown |
| HY-112823A | Almonertinib mesylate | Inhibitor | 99.67% | Unkown |
| HY-135815A | Mobocertinib succinate | Inhibitor | 99.83% | Yes |
| HY-50896R | Erlotinib (Standard) | Inhibitor | 99.97% | Unkown |
| HY-16069A | Tucatinib hemiethanolate | Inhibitor | 98.82% | Yes |
| HY-15164 | Icotinib Hydrochloride | Inhibitor | 99.96% | Yes |
| HY-50895R | Gefitinib (Standard) | Inhibitor | 99.94% | Unkown |
| HY-118263 | Dacomitinib hydrate | Inhibitor | 99.54% | Unkown |
| HY-12008R | Erlotinib Hydrochloride (Standard) | Inhibitor | 99.73% | Unkown |
| HY-135815B | Mobocertinib mesylate | Inhibitor | / | Unkown |
| HY-50898C | Lapatinib tosylate | Inhibitor | / | Unkown |
| HY-10261D | Afatinib oxalate | Inhibitor | / | Unkown |
| HY-50895B | Gefitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-101820A | Simotinib hydrochloride | Inhibitor | / | Unkown |
| HY-15164AR | Icotinib (Standard) | Inhibitor | / | Unkown |
| HY-50898BR | Lapatinib ditosylate monohydrate (Standard) | Inhibitor | 98.15% | Unkown |
| HY-50895AR | Gefitinib hydrochloride (Standard) | Inhibitor | 99.46% | Unkown |
| HY-12008A | Erlotinib mesylate | Inhibitor | / | Unkown |
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9977 | Amivantamab | Inhibitor | 99.90% | Unkown |
| HY-P9912 | Pertuzumab | Inhibitor | 99.80% | Unkown |
| HY-P99041 | Panitumumab | Inhibitor | 99.77% | Unkown |
| HY-P99380 | Zanidatamab | Inhibitor | 98.56% | Unkown |
| HY-P99507 | Zenocutuzumab | Inhibitor | 99.9% | Unkown |
| HY-P9968 | Nimotuzumab | Inhibitor | 96.80% | Unkown |
| HY-P9964 | Necitumumab | Inhibitor | 99.82% | Unkown |
| HY-P99030 | Margetuximab | Inhibitor | ≥99.0% | Unkown |
Clinical Phase
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Phase |
|---|---|---|---|---|
| HY-14596 | Genistein | Inhibitor | 99.82% | Phase 4 |
| HY-137433 | Befotertinib | Inhibitor | 99.77% | Phase 4 |
| HY-131686 | Ganglioside GT1b (bovine) ammonium | Activator | 98.0% | Phase 4 |
| HY-50895G | Gefitinib (GMP) | Inhibitor | / | Phase 4 |
| HY-P99813 | Patritumab deruxtecan | 99.08% | Phase 3 | |
| HY-P99406 | Petosemtamab | Degrader | 99.90% | Phase 3 |
| HY-18750 | Zorifertinib | Inhibitor | 99.37% | Phase 3 |
| HY-171265 | Becotatug vedotin | Inhibitor | 96.99% | Phase 3 |
| HY-15729 | Rociletinib | Inhibitor | 99.67% | Phase 3 |
| HY-15730 | Poziotinib | Inhibitor | 99.96% | Phase 3 |
| HY-132259 | Depatuxizumab mafodotin | 99.65% | Phase 3 | |
| HY-12872 | Nazartinib | Inhibitor | 99.53% | Phase 3 |
| HY-164762 | Trastuzumab rezetecan | Inhibitor | 98.01% | Phase 3 |
| HY-112299 | Zipalertinib | Inhibitor | 99.62% | Phase 3 |
| HY-139920 | Oritinib | Inhibitor | 99.59% | Phase 3 |
| HY-19803 | Naquotinib mesylate | Inhibitor | 98.06% | Phase 3 |
| HY-19816A | Avitinib maleate | Inhibitor | 99.86% | Phase 3 |
| HY-13314 | Tesevatinib | Inhibitor | 99.41% | Phase 3 |
| HY-120590 | Ruserontinib | Inhibitor | 99.32% | Phase 3 |
| HY-P990697 | Anvatabart | Inhibitor | 98.15% | Phase 3 |
| HY-138751A | limertinib diTFA | Inhibitor | 98.96% | Phase 3 |
| HY-118998 | TX2-121-1 | Degrader | 98.01% | Phase 3 |
| HY-10530A | Varlitinib tosylate | Inhibitor | / | Phase 3 |
| HY-106204 | Nelipepimut-S | / | Phase 3 | |
| HY-N14349 | Asterriquinone | Inhibitor | / | Phase 3 |
| HY-109189A | Rezivertinib hydrochloride | Inhibitor | / | Phase 3 |
| HY-172820 | Trastuzumab envedotin | Inhibitor | / | Phase 3 |
| HY-13050 | Sapitinib | Inhibitor | 99.93% | Phase 2 |
| HY-10367 | Canertinib | Inhibitor | 99.74% | Phase 2 |
| HY-P99268 | Seribantumab | Inhibitor | 96.043% | Phase 2 |
| HY-32718 | Pelitinib | Inhibitor | 99.13% | Phase 2 |
| HY-153268 | Silevertinib | Inhibitor | 99.74% | Phase 2 |
| HY-10045 | AEE788 | Inhibitor | 98.39% | Phase 2 |
| HY-14674 | CP-724714 | Inhibitor | 98.72% | Phase 2 |
| HY-10333 | BMS-690514 | Inhibitor | 99.68% | Phase 2 |
| HY-19985 | PF-06459988 | Inhibitor | 99.10% | Phase 2 |
| HY-12972 | Mavelertinib | Inhibitor | 99.34% | Phase 2 |
| HY-17632 | Tarloxotinib bromide | Inhibitor | 98.75% | Phase 2 |
| HY-172429A | Enozertinib hemihydrate | Inhibitor | 99.98% | Phase 2 |
| HY-19815 | Olafertinib | Inhibitor | 99.51% | Phase 2 |
| HY-10251 | BMS-599626 | Inhibitor | 98.56% | Phase 2 |
| HY-107367A | Epertinib hydrochloride | Inhibitor | 98.15% | Phase 2 |
| HY-19909 | NRC-2694 | Antagonist | 99.84% | Phase 2 |
| HY-155537 | Pruvonertinib | Inhibitor | 99.50% | Phase 2 |
| HY-W423595 | BEBT-109 | Inhibitor | 98.72% | Phase 2 |
| HY-153974 | BBT-176 | Inhibitor | 98.98% | Phase 2 |
| HY-107367 | Epertinib | Inhibitor | ≥98.0% | Phase 2 |
| HY-P9994 | Pertuzumab zuvotolimod | Inhibitor | 98.64% | Phase 2 |
| HY-P991240 | CDX-3379 | Inhibitor | 99.38% | Phase 2 |
| HY-P991092 | IBI-334 | Inhibitor | 98.18% | Phase 2 |
| HY-177414 | BB-1701 | Inhibitor | 98.81% | Phase 2 |
| HY-101756 | SDZ281-977 | 98.00% | Phase 2 | |
| HY-164387A | Sutetinib maleate | Inhibitor | / | Phase 2 |
| HY-10223 | CUDC-101 | Inhibitor | 99.05% | Phase 1 |
| HY-13501 | Mubritinib | Inhibitor | 99.91% | Phase 1 |
| HY-164202 | ORM-5029 | Inhibitor | 96.53% | Phase 1 |
| HY-18957 | Lifirafenib | Inhibitor | 98.01% | Phase 1 |
| HY-144680 | BLU-945 | Inhibitor | 99.61% | Phase 1 |
| HY-14346 | PD153035 | Inhibitor | 98.56% | Phase 1 |
| HY-171124 | Tilatamig samrotecan | Inhibitor | 95.26% | Phase 1 |
| HY-136789 | Tuxobertinib | Inhibitor | 99.88% | Phase 1 |
| HY-15196 | TAK-285 | Inhibitor | 98.99% | Phase 1 |
| HY-103443 | HKI-357 | Inhibitor | 99.24% | Phase 1 |
| HY-B0794 | AZ7550 | Inhibitor | 97.09% | Phase 1 |
| HY-116437 | Selatinib | Inhibitor | 98.56% | Phase 1 |
| HY-155079 | DZD1516 | Inhibitor | 99.62% | Phase 1 |
| HY-101820 | Simotinib | Inhibitor | 99.39% | Phase 1 |
| HY-10346 | AV-412 | Inhibitor | 99.17% | Phase 1 |
| HY-P99685 | Laprituximab emtansine | Inhibitor | 97.66% | Phase 1 |
| HY-153110 | Larotinib | Inhibitor | 99.50% | Phase 1 |
| HY-139300 | Epitinib | Inhibitor | 99.95% | Phase 1 |
| HY-164694 | Emupertinib | Inhibitor | 99.10% | Phase 1 |
| HY-171747 | AMT-562 | Antagonist | 98.65% | Phase 1 |
| HY-177895 | IAM1363 | Inhibitor | 99.40% | Phase 1 |
| HY-111553 | TAS0728 | Inhibitor | 99.71% | Phase 1 |
| HY-128778 | Gozanertinib | Inhibitor | 98.30% | Phase 1 |
| HY-164307 | Pebezertinib | Inhibitor | 99.56% | Phase 1 |
| HY-164464 | BPI-15086 | Inhibitor | 99.08% | Phase 1 |
| HY-15732 | BGB-102 | Inhibitor | 99.52% | Phase 1 |
| HY-104066A | Theliatinib tartrate | / | Phase 1 | |
| HY-181954 | ZW-49 | Inhibitor | / | Phase 1 |
| HY-153856 | TAS2940 | Inhibitor | / | Phase 1 |
| HY-110333 | BMS-599626 dihydrochloride | Inhibitor | / | Phase 1 |
| HY-110039 | BIBX 1382 dihydrochloride | Inhibitor | / | Phase 1 |
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Phase |
|---|---|---|---|---|
| HY-P99041A | Panitumumab (anti-EGFR) | Inhibitor | 99.02% | Phase 4 |
| HY-P99969 | Inetetamab | Inhibitor | 96.54% | Phase 4 |
| HY-P99854A | Disitamab (powder) | Inhibitor | 98.44% | Phase 4 |
| HY-P99041B | Panitumumab (powder) | Inhibitor | / | Phase 4 |
| HY-P99676 | Izalontamab | Inhibitor | 99.89% | Phase 3 |
| HY-P99849 | Depatuxizumab | Inhibitor | 99.58% | Phase 3 |
| HY-P99155 | Zalutumumab | 98.34% | Phase 3 | |
| HY-P990049 | Becotatug | Inhibitor | 99.00% | Phase 3 |
| HY-P99437 | Anbenitamab | Inhibitor | 99.22% | Phase 3 |
| HY-P99455 | Bafisontamab | Inhibitor | 99.9% | Phase 3 |
| HY-P99831 | Coprelotamab | / | Phase 3 | |
| HY-P991588 | HLX-22 | Antagonist | 99.47% | Phase 3 |
| HY-P991508 | Sym004 | Inhibitor | 98.97% | Phase 3 |
| HY-P99155A | Zalutumumab (powder) | Inhibitor | / | Phase 3 |
| HY-P9969 | Matuzumab | 99.50% | Phase 2 | |
| HY-P99936 | Elgemtumab | Inhibitor | 99.00% | Phase 2 |
| HY-P99778 | Ontuxizumab | 99.85% | Phase 2 | |
| HY-P990314 | AFM24 | Inhibitor | 96.26% | Phase 2 |
| HY-P99295 | Imgatuzumab | Inhibitor | 99.41% | Phase 2 |
| HY-P990071 | Fepixnebart | Inhibitor | 96.46% | Phase 2 |
| HY-P99605 | Cinrebafusp alfa | Inhibitor | 98.53% | Phase 2 |
| HY-P99306 | Modotuximab | Inhibitor | 99.08% | Phase 2 |
| HY-P99628 | Futuximab | Inhibitor | 98.09% | Phase 2 |
| HY-P991571 | GC1118 | 99.22% | Phase 2 | |
| HY-P991237 | Nezutatug | Inhibitor | 99.9% | Phase 2 |
| HY-P990913 | Dalmitamig | 97.158% | Phase 2 | |
| HY-P99672 | Istiratumab | Inhibitor | 98.45% | Phase 2 |
| HY-P991238 | MEDI4276 Antibody | Inhibitor | 96.5212% | Phase 2 |
| HY-P991507 | SCT200 | Inhibitor | 99.09% | Phase 2 |
| HY-P991572 | MM-151 | Antagonist | / | Phase 2 |
| HY-P99500 | Cetuximab sarotalocan | Inhibitor | / | Phase 2 |
| HY-P991233 | BAT1006 | Inhibitor | / | Phase 2 |
| HY-P991524 | MM-111 | Inhibitor | / | Phase 2 |
| HY-P99896 | Runimotamab | 99.00% | Phase 1 | |
| HY-P99386 | Vesencumab | Inhibitor | 99.34% | Phase 1 |
| HY-P99304 | Lumretuzumab | Inhibitor | ≥99.0% | Phase 1 |
| HY-P991984 | SIBP-03 | Inhibitor | / | Phase 1 |
| HY-P991235 | FS102 | Degrader | / | Phase 1 |
| HY-P990609 | KHK-2866 | 98.23% | Phase 1 | |
| HY-P991244 | REGN-1400 | Inhibitor | / | Phase 1 |
Pre-clinical Phase
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-12000 | AG490 | Inhibitor | 99.86% | Unkown |
| HY-P0221 | PACAP (1-38), human, ovine, rat | Inducer | 99.99% | Unkown |
| HY-13524 | AG-1478 | Inhibitor | 99.57% | Unkown |
| HY-P99275 | Patritumab | Inhibitor | 99.28% | Unkown |
| HY-P10408 | Candidalysin | Activator | 99.81% | Unkown |
| HY-164702 | BL-B01D1 | Inhibitor | 98.59% | Unkown |
| HY-101084 | NSC 228155 | Activator | 99.58% | Unkown |
| HY-164992 | Trastuzumab vedotin | Inhibitor | 98.05% | Unkown |
| HY-13595 | Chrysophanol | Inhibitor | 99.73% | Unkown |
| HY-N0280 | Corosolic acid | 99.95% | Unkown | |
| HY-16558 | Butein | Inhibitor | 99.64% | Unkown |
| HY-N2409 | Delphinidin chloride | Inhibitor | 98.0% | Unkown |
| HY-171135 | Cetuximab MMAE | Inhibitor | 99.64% | Unkown |
| HY-100848 | TX1-85-1 | Inhibitor | 99.65% | Unkown |
| HY-12461 | WS6 | Activator | 99.30% | Unkown |
| HY-100958 | 4-DAMP | Inhibitor | 99.96% | Unkown |
| HY-B0793 | AZ-5104 | Inhibitor | 99.91% | Unkown |
| HY-156698 | HJM-561 | Degrader | 99.52% | Unkown |
| HY-N7922 | Urolithin M5 | 97.31% | Unkown | |
| HY-100742 | GNE-140 racemate | Inhibitor | 99.25% | Unkown |
| HY-123921 | Gefitinib-based PROTAC 3 | Degrader | 99.98% | Unkown |
| HY-19816 | Avitinib | Inhibitor | 99.95% | Unkown |
| HY-15644 | Tyrphostin 23 | Inhibitor | 98.19% | Unkown |
| HY-14596R | Genistein (Standard) | Inhibitor | 98.70% | Unkown |
| HY-168438 | ERBB agonist-1 | Agonist | 99.16% | Unkown |
| HY-N0447 | 8-Gingerol | Inhibitor | 99.72% | Unkown |
| HY-108052 | Delphinidin 3-glucoside chloride | Inhibitor | 99.89% | Unkown |
| HY-162713 | MTX-531 | Inhibitor | 99.87% | Unkown |
| HY-120852 | JG26 | Inhibitor | 98.14% | Unkown |
| HY-112411 | PD 174265 | Inhibitor | 98.35% | Unkown |
| HY-W016412 | Coenzyme Q0 | Inhibitor | 99.79% | Unkown |
| HY-129550 | BI-4020 | Inhibitor | 99.30% | Unkown |
| HY-13896 | PD168393 | Inhibitor | 98.01% | Unkown |
| HY-41404 | Piperonylic acid | 99.94% | Unkown | |
| HY-109189 | Rezivertinib | Inhibitor | 99.62% | Unkown |
| HY-48999A | FSK hydrochloride | 99.97% | Unkown | |
| HY-131864 | SJF-1528 | Degrader | 99.45% | Unkown |
| HY-100434 | PD-161570 | Inhibitor | 98.78% | Unkown |
| HY-141640 | MS154 | Inhibitor | 99.71% | Unkown |
| HY-138751 | limertinib | Inhibitor | 99.15% | Unkown |
| HY-N2450 | Sulforaphene | Inhibitor | 99.78% | Unkown |
| HY-N0211 | Cyasterone | Inhibitor | 99.58% | Unkown |
| HY-18609 | PD158780 | Inhibitor | 99.47% | Unkown |
| HY-W782083 | p-SCN-Bn-NOTA trihydrochloride | 99.75% | Unkown | |
| HY-P990957 | Ficerafusp alfa | Substrate | 99.71% | Unkown |
| HY-155736 | MAPK-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-14596S | Genistein-d4 | Inhibitor | 98.81% | Unkown |
| HY-125168 | EGA | Modulator | 99.76% | Unkown |
| HY-N2184 | Furanodienone | 99.90% | Unkown | |
| HY-10530 | Varlitinib | Inhibitor | 99.92% | Yes |
| HY-N7005 | Clitorin | Inhibitor | 99.45% | Unkown |
| HY-141676 | HyT36 | Degrader | 96.0% | Unkown |
| HY-15375 | Allitinib | Inhibitor | 98.88% | Unkown |
| HY-100213 | EAI045 | Inhibitor | 99.06% | Unkown |
| HY-N0891 | Tubeimoside II | Inhibitor | 99.90% | Unkown |
| HY-10322 | Falnidamol | Inhibitor | 98.36% | Unkown |
| HY-138916 | PF-06672131 | Inhibitor | 99.47% | Unkown |
| HY-10367A | Canertinib dihydrochloride | Inhibitor | 99.68% | Unkown |
| HY-157229 | STX-721 | Inhibitor | 98.43% | Unkown |
| HY-156712 | Depatuxizumab MMAE | Inhibitor | 99.73% | Unkown |
| HY-20878 | Tyrphostin AG 879 | Inhibitor | 99.26% | Unkown |
| HY-115605 | CN009543V | Agonist | 99.37% | Unkown |
| HY-N9330 | Broussoflavonol F | Inhibitor | 98.11% | Unkown |
| HY-10261B | (E/Z)-Afatinib | Inhibitor | 99.98% | Unkown |
| HY-18963 | Lavendustin A | Inhibitor | 99.09% | Unkown |
| HY-114243 | DpC | Modulator | 98.73% | Unkown |
| HY-B0794B | AZ7550 Mesylate | Inhibitor | 98.70% | Unkown |
| HY-131865 | SJF-1521 | Degrader | 99.65% | Unkown |
| HY-P99866 | Duligotuzumab | Inhibitor | 99.17% | Unkown |
| HY-123578 | NSC689857 | Inhibitor | 99.49% | Unkown |
| HY-N6942 | Mogroside IV-A | Inhibitor | 99.9% | Unkown |
| HY-124813 | PDZ1i | Inhibitor | 99.29% | Unkown |
| HY-N2510 | Myristicin | Inhibitor | 99.89% | Unkown |
| HY-161536 | PROTAC EGFR degrader 9 | Inhibitor | 98.35% | Unkown |
| HY-N2524 | Camelliaside A | Ligand | 99.65% | Unkown |
| HY-104066 | Theliatinib | Inhibitor | 99.72% | Unkown |
| HY-109061B | Lazertinib mesylate | Inhibitor | 99.85% | Unkown |
| HY-108484 | PP 3 | Inhibitor | 99.20% | Unkown |
| HY-10325 | CL-387785 | Inhibitor | 99.31% | Unkown |
| HY-157581 | MS39 | Degrader | 99.89% | Unkown |
| HY-108016 | Peruvoside | Inhibitor | 99.32% | Unkown |
| HY-134877 | BAY 2476568 | Inhibitor | 99.88% | Unkown |
| HY-13464 | ALK-IN-1 | Inhibitor | 99.42% | Unkown |
| HY-112097 | E260 | Inhibitor | 99.92% | Unkown |
| HY-12026 | WZ4002 | Inhibitor | 98.99% | Unkown |
| HY-137191 | CH7233163 | Inhibitor | 99.41% | Unkown |
| HY-N2445 | Flavokawain C | Inhibitor | 99.79% | Unkown |
| HY-150611 | EGFR-IN-70 | Inhibitor | 98.12% | Unkown |
| HY-147858 | PROTAC EGFR degrader 7 | Degrader | 99.85% | Unkown |
| HY-115481 | EphB1-IN-1 | Inhibitor | 99.51% | Unkown |
| HY-19729 | Naquotinib | Inhibitor | 98.10% | Unkown |
| HY-107364 | MTX-211 | Inhibitor | 99.81% | Unkown |
| HY-172429 | Enozertinib | Inhibitor | 98.86% | Unkown |
| HY-147219A | SIAIS164018 hydrochloride | Degrader | 98.06% | Unkown |
| HY-N4201 | β-Hydroxyisovalerylshikonin | Inhibitor | 99.83% | Unkown |
| HY-103442 | CGP52411 | Inhibitor | 99.82% | Unkown |
| HY-114858 | Epiblastin A | Inhibitor | 99.44% | Unkown |
| HY-15772S | Osimertinib-d6 | Inhibitor | 99.70% | Unkown |
| HY-128862 | TQB-3804 | Inhibitor | 99.76% | Unkown |
| HY-12013 | PD153035 Hydrochloride | Inhibitor | 99.48% | Unkown |
| HY-128576 | DS21360717 | 99.80% | Unkown | |
| HY-162299 | EGFR kinase inhibitor 3 | Inhibitor | 99.03% | Unkown |
| HY-P991748 | Anti-Human/Mouse Amphiregulin Antibody (AR37) | Inhibitor | 99.544% | Unkown |
| HY-15844 | AG-825 | Inhibitor | 98.13% | Unkown |
| HY-17499 | EGFR-IN-12 | Inhibitor | 99.60% | Unkown |
| HY-W018800 | 4(3H)-Quinazolinone | Inhibitor | 99.89% | Unkown |
| HY-13895 | WHI-P154 | Inhibitor | 98.77% | Unkown |
| HY-B1394 | Khellin | Inhibitor | 99.66% | Unkown |
| HY-163094 | EGFR-IN-95 | Inhibitor | 98.76% | Unkown |
| HY-13897 | CNX-2006 | Inhibitor | 98.00% | Unkown |
| HY-12001 | WZ-3146 | Inhibitor | 99.28% | Unkown |
| HY-161275 | BI-4732 | Inhibitor | 98.81% | Unkown |
| HY-147183B | JBJ-09-063 hydrochloride | Inhibitor | 99.37% | Unkown |
| HY-12010 | BMS-599626 Hydrochloride | Inhibitor | 98.90% | Unkown |
| HY-147941A | MS9427 TFA | Degrader | 98.38% | Unkown |
| HY-130616 | EGFR-IN-11 | Inhibitor | 98.76% | Unkown |
| HY-111415 | EGFR-IN-5 | Inhibitor | 99.49% | Unkown |
| HY-144304 | PROTAC EGFR degrader 2 | Inhibitor | 95.09% | Unkown |
| HY-153796 | PROTAC Her3 Degrader-8 | Degrader | 99.60% | Unkown |
| HY-161408 | GePhos1 | 98.88% | Unkown | |
| HY-172470 | DSPE-PEG2000-GE11 | 95.29% | Unkown | |
| HY-18603 | FIIN-3 | Inhibitor | 99.01% | Unkown |
| HY-147942 | MS9449 | Degrader | 98.95% | Unkown |
| HY-13427 | Allitinib tosylate | Inhibitor | 99.11% | Unkown |
| HY-139617 | Sec61-IN-3 | Inhibitor | 99.33% | Unkown |
| HY-136430 | JCN037 | Inhibitor | 99.09% | Unkown |
| HY-P5314 | OK2 | Inhibitor | 99.13% | Unkown |
| HY-117155 | PKI-166 | Inhibitor | 98.92% | Unkown |
| HY-N1073 | Wighteone | Inhibitor | 98.71% | Unkown |
| HY-110406 | 13(S)-HPODE | Activator | 95.05% | Unkown |
| HY-N1988 | Cucurbitacin IIa | Inhibitor | 99.90% | Unkown |
| HY-P990755 | Pamvatamig | 98.00% | Unkown | |
| HY-161537 | EGFR ligand-9 | Inhibitor | 98.80% | Unkown |
| HY-175252 | PROTAC EGFR degrader 14 | Degrader | 99.26% | Unkown |
| HY-101960A | Tyrphostin A51 | Inhibitor | 99.76% | Unkown |
| HY-P2503 | EGFR Protein Tyrosine Kinase Substrate | 99.46% | Unkown | |
| HY-161633 | PROTAC EGFR degrader 11 | Degrader | 99.20% | Unkown |
| HY-153901 | PROTAC EGFR degrader 8 | Degrader | 98.90% | Unkown |
| HY-146349 | PROTAC EGFR degrader 4 | Degrader | 99.70% | Unkown |
| HY-P4082 | ErbB-2-binding peptide-1 | Ligand | 99.52% | Unkown |
| HY-149530 | EGFR-IN-86 | Inhibitor | 99.92% | Unkown |
| HY-43533 | Tarlox-TKI | Inhibitor | 98.79% | Unkown |
| HY-12029 | WZ8040 | Inhibitor | 98.29% | Unkown |
| HY-163428 | Perzebertinib | Inhibitor | 99.85% | Unkown |
| HY-138627A | AST5902 trimesylate | Inhibitor | 98.19% | Unkown |
| HY-150023 | BI-1622 | Inhibitor | 98.02% | Unkown |
| HY-147183A | JBJ-09-063 TFA | Inhibitor | 99.64% | Unkown |
| HY-W013857 | Lavendustin C | Inhibitor | 98.17% | Unkown |
| HY-161126 | EGFR-IN-98 | Inhibitor | 99.12% | Unkown |
| HY-175839 | PROTAC EGFR degrader 15 | Degrader | 99.23% | Unkown |
| HY-P99948 | Etevritamab | 97.00% | Unkown | |
| HY-123952 | RTC-5 | Inhibitor | 99.37% | Unkown |
| HY-P11308 | Cys-GE11 | 98.03% | Unkown | |
| HY-124674A | CCT365623 hydrochloride | Inhibitor | 98.07% | Unkown |
| HY-123035 | Gamendazole | Inhibitor | 99.44% | Unkown |
| HY-RS04209 | EGFR Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-19985A | (3S,4S)-PF-06459988 | 98.97% | Unkown | |
| HY-103440 | EGFR/ErbB-2/ErbB-4 inhibitor-3 | Inhibitor | 96.78% | Unkown |
| HY-79511 | FAAH-IN-2 | Ligand | 99.12% | Unkown |
| HY-P10792 | HER2-targeted peptide H6F | 98.85% | Unkown | |
| HY-101219 | VEGFR-IN-1 | Inhibitor | 99.07% | Unkown |
| HY-101429 | RG13022 | Inhibitor | 96.74% | Unkown |
| HY-177008 | PROTAC HER2 degrader-1 | Degrader | 98.0% | Unkown |
| HY-157579 | MS154N | 99.30% | Unkown | |
| HY-103566 | LY456236 | Inhibitor | 99.57% | Unkown |
| HY-P1828A | EGFRvIII peptide (PEPvIII) TFA | 98.73% | Unkown | |
| HY-112293 | GW2974 | 99.16% | Unkown | |
| HY-15336 | AG 555 | Inhibitor | 98.0% | Unkown |
| HY-101041 | (E)-AG 556 | Inhibitor | 99.91% | Unkown |
| HY-126320 | EGFR-IN-8 | Inhibitor | 98.01% | Unkown |
| HY-164919 | Calotatug ginistinag | Inhibitor | 95.94% | Unkown |
| HY-100214 | EAI001 | Inhibitor | 99.93% | Unkown |
| HY-142283AS | Dosimertinib mesylate | Inhibitor | 99.50% | Unkown |
| HY-150024 | BI-4142 | Inhibitor | 98.02% | Unkown |
| HY-15769 | WHI-P180 | Inhibitor | 99.84% | Unkown |
| HY-N6932 | Voacamine | 99.64% | Unkown | |
| HY-N7424 | 4,7-Dihydroxycoumarin | Inhibitor | 98.25% | Unkown |
| HY-112474 | Tyrphostin AG 112 | Inhibitor | 98.31% | Unkown |
| HY-P99618 | Fidasimtamab | Inhibitor | 95.00% | Unkown |
| HY-101042 | AG-494 | Inhibitor | 98.69% | Unkown |
| HY-111138 | CZC-8004 | Inhibitor | 99.81% | Unkown |
| HY-131864A | SJF-1528 hemihydrate | Degrader | 98.90% | Unkown |
| HY-142512 | EGFR-IN-24 | Inhibitor | 98.71% | Unkown |
| HY-13984 | NT-1 | Inhibitor | 99.40% | Unkown |
| HY-15729A | Rociletinib hydrobromide | Inhibitor | 98.04% | Yes |
| HY-101450 | PF-6274484 | Inhibitor | 98.76% | Unkown |
| HY-107459 | (E/Z)-AG490 | Inhibitor | 99.71% | Unkown |
| HY-118532 | Tyrphostin AG30 | Inhibitor | 98.51% | Unkown |
| HY-157480 | EGFR/AURKB-IN-1 | Inhibitor | 99.43% | Unkown |
| HY-156284 | EGFR-IN-89 | Inhibitor | 98.75% | Unkown |
| HY-135805B | (Rac)-JBJ-04-125-02 acetate | 96.03% | Unkown | |
| HY-P10224A | G7-18NATE TFA | 98.06% | Unkown | |
| HY-N6577 | Astragaloside VI | 99.95% | Unkown | |
| HY-12806 | AG1557 | Inhibitor | 99.54% | Unkown |
| HY-172920 | Wnt/β-catenin-IN-6 | Inhibitor | 98.34% | Unkown |
| HY-112420 | EGFR/ErbB-2-IN-2 | Inhibitor | 99.45% | Unkown |
| HY-119944 | JND3229 | Inhibitor | 99.38% | Unkown |
| HY-141481 | DP-C-4 | Inhibitor | 98.15% | Unkown |
| HY-153110A | Larotinib mesylate hydrate | Inhibitor | 98.66% | Unkown |
| HY-P99630 | Gancotamab antibody | Inhibitor | ≥99.0% | Unkown |
| HY-101006 | Methyl 2,5-dihydroxycinnamate | Inhibitor | 99.77% | Unkown |
| HY-143337 | EGFR-IN-47 | Inhibitor | 96.01% | Unkown |
| HY-112345 | PD-089828 | Inhibitor | 98.07% | Unkown |
| HY-103441 | JNJ28871063 hydrochloride | Inhibitor | 98.36% | Unkown |
| HY-RS04466 | ERBB2 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-15801 | HG-14-10-04 | Inhibitor | 98.53% | Unkown |
| HY-139997 | DDC-01-163 | Degrader | 99.05% | Unkown |
| HY-158149 | T-1-PMPA | Inhibitor | 99.70% | Unkown |
| HY-131686A | Ganglioside GT1b (porcine) ammonium | Activator | 98% | Unkown |
| HY-133780 | Afatinib impurity 11 | Inhibitor | 99.10% | Unkown |
| HY-170820 | XYD049 | Inhibitor | 99.46% | Unkown |
| HY-164763 | SHR-A1201 | Inhibitor | 97.35% | Unkown |
| HY-100923 | H-9 Dihydrochloride | Inhibitor | 98.98% | Unkown |
| HY-101426 | RG14620 | Inhibitor | 99.02% | Unkown |
| HY-P1855 | HER2/neu (654-662) GP2 | 98.26% | Unkown | |
| HY-N1166 | Tephrosin | 98.02% | Unkown | |
| HY-161781 | HVH-2930 | Inhibitor | 96.54% | Unkown |
| HY-162890 | EGFR-IN-122 | Inhibitor | 99.98% | Unkown |
| HY-50898S | Lapatinib-d4 | Inhibitor | 99.02% | Unkown |
| HY-156741A | EGFR-IN-87 hydrochloride | Inhibitor | 98.0% | Unkown |
| HY-50896S | Erlotinib-d6 | Inhibitor | 99.84% | Unkown |
| HY-P991662 | AMG-595 Antibody | 96.94% | Unkown | |
| HY-179572 | STA-013 | Inhibitor | 99.18% | Unkown |
| HY-172414 | Andamertinib | Inhibitor | 99.06% | Unkown |
| HY-151159 | DHFR-IN-4 | Inhibitor | 99.19% | Unkown |
| HY-145960A | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 formic | Agonist | 97.70% | Unkown |
| HY-RS04472 | ERBB4 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-100064 | O-Desmethyl gefitinib | Inhibitor | 99.40% | Unkown |
| HY-149889 | EGFR-IN-78 | Inhibitor | 99.57% | Unkown |
| HY-101522 | CHMFL-EGFR-202 | Inhibitor | 99.75% | Unkown |
| HY-161927 | EGFR-TK-IN-4 | Inhibitor | 99.90% | Unkown |
| HY-P11078A | LARLLT TFA | 99.89% | Unkown | |
| HY-157582 | MS39N | Control | 98.0% | Unkown |
| HY-13450 | ZM 449829 | Inhibitor | 99.73% | Unkown |
| HY-156872 | MTX-216 | Inhibitor | / | Unkown |
| HY-50895S2 | Gefitinib-d3 | Inhibitor | 98.39% | Unkown |
| HY-113599 | Isoprocurcumenol | Activator | 95.41% | Unkown |
| HY-112870AS | Firmonertinib-d3 mesylate | 99.00% | Unkown | |
| HY-50895S | Gefitinib-d8 | Inhibitor | 98.42% | Unkown |
| HY-131067 | EMI56 | Inhibitor | 99.36% | Unkown |
| HY-19617A | EGFR-IN-1 hydrochloride | Inhibitor | / | Unkown |
| HY-100962 | (E)-AG 99 | Inhibitor | 98.12% | Unkown |
| HY-135805A | (Rac)-JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-19617 | EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-152852 | Mefatinib free base | Inhibitor | 99.40% | Unkown |
| HY-132842A | (S)-Sunvozertinib | Inhibitor | 99.05% | Unkown |
| HY-147941 | MS9427 | Degrader | 95.29% | Unkown |
| HY-147183 | JBJ-09-063 | Inhibitor | / | Unkown |
| HY-139300A | Epitinib succinate | Inhibitor | 99.01% | Unkown |
| HY-115716 | EGFR-IN-17 | Inhibitor | 98.18% | Unkown |
| HY-138627 | AST5902 | Inhibitor | / | Unkown |
| HY-130608 | Mutated EGFR-IN-3 | Inhibitor | / | Unkown |
| HY-138072 | EMI1 | Inhibitor | 99.45% | Unkown |
| HY-103439 | GW583340 dihydrochloride | Inhibitor | / | Unkown |
| HY-131088A | N3-PEG8-Phe-Lys-PABC-Gefitinib TFA | Inhibitor | / | Unkown |
| HY-170928 | DA-0157 | Inhibitor | 99.59% | Unkown |
| HY-183682 | AZ14289671 | Inhibitor | 99.77% | Unkown |
| HY-151048 | JBJ-07-149 | Inhibitor | 99.09% | Unkown |
| HY-183068 | AP4-43 | Inhibitor | 99.76% | Unkown |
| HY-149636 | Multi-target kinase inhibitor 2 | Inhibitor | 99.82% | Unkown |
| HY-155358 | Os30 | Inhibitor | 98.34% | Unkown |
| HY-101958 | Tyrphostin 25 | Inhibitor | 99.00% | Unkown |
| HY-147858A | PROTAC EGFR degrader 7 diTFA | Degrader | 97.15% | Unkown |
| HY-155285 | YS-363 | Inhibitor | 99.52% | Unkown |
| HY-111452 | EGFR-IN-85 | Inhibitor | / | Unkown |
| HY-P3744 | pp60v-src Autophosphorylation site | 99.93% | Unkown | |
| HY-108486 | Herbimycin A | Degrader | 99% | Unkown |
| HY-156912 | Tyrosine kinase-IN-7 | Inhibitor | 99.25% | Unkown |
| HY-101007A | (+)-Tyrphostin B44 | Inhibitor | 99.10% | Unkown |
| HY-161618 | MJ04 | Inhibitor | 98.08% | Unkown |
| HY-129510 | 4-Methyl erlotinib | Inhibitor | 99.34% | Unkown |
| HY-50895S1 | Gefitinib-d6 | Inhibitor | 98.2% | Unkown |
| HY-147219 | SIAIS164018 | Degrader | / | Unkown |
| HY-135805 | JBJ-04-125-02 | Inhibitor | / | Unkown |
| HY-15772S3 | Asandeutertinib | Inhibitor | 99.75% | Unkown |
| HY-157413 | YS-67 | Inhibitor | 99.41% | Unkown |
| HY-N10103 | Neoschaftoside | Modulator | 98.04% | Unkown |
| HY-N6651 | Isocryptotanshinone | Inhibitor | ≥98.0% | Unkown |
| HY-15772S1 | Osimertinib-13C,d3 | 99.14% | Unkown | |
| HY-12872B | Nazartinib S-enantiomer | 95.10% | Unkown | |
| HY-14347 | EBE-A22 | Control | 99.86% | Unkown |
| HY-155005 | EGFR mutant-IN-2 | Inhibitor | 97.0% | Unkown |
| HY-131088 | N3-PEG8-Phe-Lys-PABC-Gefitinib | Inhibitor | / | Unkown |
| HY-126850 | 4-Epidoxycycline | / | Unkown | |
| HY-P2673A | Lys-Arg-Thr-Leu-Arg-Arg acetate | / | Unkown | |
| HY-136612 | DCBA | 98.92% | Unkown | |
| HY-156741 | EGFR-IN-87 | Inhibitor | / | Unkown |
| HY-108931 | AG 1406 | Inhibitor | 99.03% | Unkown |
| HY-126319 | SU5204 | Inhibitor | 99.46% | Unkown |
| HY-P992128 | Rinumafusp alfa | Inhibitor | 97.09% | Unkown |
| HY-150610 | EGFR-IN-69 | Inhibitor | 99.58% | Unkown |
| HY-P2673 | Lys-Arg-Thr-Leu-Arg-Arg | / | Unkown | |
| HY-162254 | EGFR/ACK1-IN-1 | Inhibitor | 98.19% | Unkown |
| HY-13272S2 | Dacomitinib-d10 dihydrochloride | Inhibitor | ≥95.0% | Unkown |
| HY-144677 | pan-HER-IN-2 | Inhibitor | 98.10% | Unkown |
| HY-145960 | MC-Val-Cit-PAB-Amide-TLR7 agonist 4 | Agonist | 99.39% | Unkown |
| HY-10346A | AV-412 free base | Inhibitor | 98.10% | Unkown |
| HY-B0794A | AZ7550 hydrochloride | Inhibitor | 98.66% | Unkown |
| HY-P991149 | Nesfrotamig | Activator | 99.22% | Unkown |
| HY-U00002 | ZD-4190 | Inhibitor | 98.08% | Unkown |
| HY-10261S | Afatinib-d6 | Inhibitor | 99.0% | Unkown |
| HY-164387 | Sutetinib | Inhibitor | 99.27% | Unkown |
| HY-153111 | EGFR/HER2-IN-9 | Inhibitor | 98.73% | Unkown |
| HY-158310 | SOS1/EGFR-IN-1 | Inhibitor | 99.54% | Unkown |
| HY-P990695 | Lunaxafusp (His Tag) | Inhibitor | / | Unkown |
| HY-P992138 | Vadalentamig | Inhibitor | 96.79% | Unkown |
| HY-12008S | Erlotinib-d6 hydrochloride | Inhibitor | 98.13% | Unkown |
| HY-100499 | Tyrphostin AG 528 | Inhibitor | 98.0% | Unkown |
| HY-19617B | EGFR-IN-1 TFA | Inhibitor | 99.38% | Unkown |
| HY-164476 | ES-072 | Inhibitor | 98.05% | Unkown |
| HY-P992130 | Rolditamig | Inhibitor | 95.26% | Unkown |
| HY-123766 | EGFR-IN-99 | Inhibitor | 98.09% | Unkown |
| HY-P990698 | Umizortamig | 96.90% | Unkown | |
| HY-W109039 | EGFR ligand-15 | 97.03% | Unkown | |
| HY-B0794S | AZ7550-d5 | Inhibitor | / | Unkown |
| HY-12872A | Nazartinib mesylate | Inhibitor | / | Unkown |
| HY-W001520 | 1-Methyl-1H-pyrrolo[2,3-b]pyridine | / | Unkown | |
| HY-21291 | SU-4313 | Modulator | 99.31% | Unkown |
| HY-188282 | Trastuzumab botidotin | / | Unkown | |
| HY-185832 | SYS6010 | Inhibitor | 98.19% | Unkown |
| HY-135914 | JBJ-02-112-05 | Inhibitor | / | Unkown |
| HY-185816 | TQB2102 | Inhibitor | / | Unkown |
| HY-19981B | Derazantinib dihydrochloride | Inhibitor | / | Unkown |
| HY-100520 | EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-142283 | Dosimertinib | Inhibitor | / | Unkown |
| HY-18750A | Zorifertinib hydrochloride | Inhibitor | / | Unkown |
| HY-163354 | EGFR-IN-103 | Inhibitor | / | Unkown |
| HY-143734 | HER2-IN-6 | / | Unkown | |
| HY-B0793S1 | AZ-5104-d2 | Inhibitor | / | Unkown |
| HY-132883 | EGFR/CSC-IN-1 | Inhibitor | / | Unkown |
| HY-139920A | Oritinib mesylate | Inhibitor | / | Unkown |
| HY-128860 | Mutated EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-189685 | BPI-361175 | Inhibitor | / | Unkown |
| HY-125841 | EGFR mutant-IN-1 | Inhibitor | / | Unkown |
| HY-168968S | ZJY-54 | Inhibitor | / | Unkown |
| HY-144048 | EGFR-IN-31 | / | Unkown | |
| HY-189682 | HS-10375 | Inhibitor | / | Unkown |
| HY-112806 | ST8155AA1 | / | Unkown | |
| HY-138298C | Trastuzumab deruxtecan (DAR4) | Inhibitor | / | Unkown |
| HY-189681 | QLH-11811 | Inhibitor | / | Unkown |
| HY-123726 | ErbB-1/ErbB-2 tyrosine kinase-IN-1 | / | Unkown | |
| HY-147407 | Imbotolimod | Inhibitor | / | Unkown |
| HY-115951 | EGFR/HER2-IN-2 | Inhibitor | / | Unkown |
| HY-152852A | Mefatinib | Inhibitor | 99.44% | Unkown |
| HY-10407G | SU 5402 (GMP) | Inhibitor | / | Unkown |
| HY-147303 | Sacibertinib | Inhibitor | / | Unkown |
| HY-131066 | EMI48 | Inhibitor | 99.45% | Unkown |
| HY-114243A | DpC hydrochloride | Modulator | / | Unkown |
| HY-137433A | Befotertinib mesylate | Inhibitor | / | Unkown |
| HY-174232 | EGFR/CA-IX-IN-1 | Inhibitor | / | Unkown |
| HY-143733 | HER2-IN-5 | Inhibitor | / | Unkown |
| HY-P9907S | 15N-Labeled Trastuzumab | / | Unkown | |
| HY-146170 | Anticancer agent 69 | Inhibitor | / | Unkown |
| HY-142681 | EGFR-IN-28 | Inhibitor | / | Unkown |
| HY-161891 | EGFR/Akt-IN-1 | Inhibitor | / | Unkown |
| HY-155969 | EGFR-IN-83 | Inhibitor | / | Unkown |
| HY-134468 | PP124 | Inhibitor | / | Unkown |
| HY-168577 | KRAS G12D inhibitor 25 | Degrader | / | Unkown |
| HY-176279 | Hsp90-IN-42 | Inhibitor | / | Unkown |
| HY-181775 | VEGFR-2/c-Met/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-155118 | EGFR-IN-81 | Inhibitor | / | Unkown |
| HY-178157 | Multi-target kinase-IN-7 | Inhibitor | / | Unkown |
| HY-P5258 | Oligopeptide-41 | Inducer | 98.05% | Unkown |
| HY-162482 | EGFR kinase inhibitor 5 | Inhibitor | / | Unkown |
| HY-13050A | Sapitinib fumarate | Inhibitor | / | Unkown |
| HY-153856A | TAS2940 fumarate | Inhibitor | / | Unkown |
| HY-180917 | PROTAC EGFR degrader 17 | Degrader | / | Unkown |
| HY-175588 | EGFR-IN-170 | Inhibitor | / | Unkown |
| HY-161603 | EGFR/HER2-IN-14 | Inhibitor | / | Unkown |
| HY-142283BS | N-Desmethyl dosimertinib | / | Unkown | |
| HY-173492 | EGFR-IN-156 | Inhibitor | / | Unkown |
| HY-156639 | EGFR/ErbB-2 inhibitor-1 | Inhibitor | / | Unkown |
| HY-158178 | EGFR T790M/L858R-IN-7 | Inhibitor | / | Unkown |
| HY-116504 | WB-308 | Inhibitor | / | Unkown |
| HY-156116 | EGFR/CDK2-IN-4 | Inhibitor | / | Unkown |
| HY-176788 | EGFR Ligand-Linker Conjugates 1 | Inhibitor | / | Unkown |
| HY-50896S1 | Erlotinib-13C6 | Inhibitor | / | Unkown |
| HY-146472 | EGFR-IN-52 | Inhibitor | / | Unkown |
| HY-17654 | BIEGi-1 | Inhibitor | / | Unkown |
| HY-162602 | EGFR-IN-115 | Inhibitor | / | Unkown |
| HY-189683 | EGFR-IN-220 | Inhibitor | / | Unkown |
| HY-107450 | PROTAC Her3-binding moiety 2 | Inhibitor | / | Unkown |
| HY-181777 | Mal-Pip-ValCit-PAB-AZ7550 | Inhibitor | / | Unkown |
| HY-157324 | EGFR-IN-94 | Inhibitor | / | Unkown |
| HY-180196 | EGFR-IN-187 | Inhibitor | / | Unkown |
| HY-175162 | EGFR ligand-20 | Ligand | / | Unkown |
| HY-144049 | EGFR-IN-32 | Inhibitor | / | Unkown |
| HY-161320 | EGFR-IN-105 | Inhibitor | / | Unkown |
| HY-163663 | AZ14133346 | Inhibitor | / | Unkown |
| HY-W714853 | (+)-Theta-cypermethrin | Ligand | / | Unkown |
| HY-12008S1 | Erlotinib-13C6 hydrochloride | Inhibitor | / | Unkown |
| HY-182914 | NGI-189 | Inhibitor | 99.29% | Unkown |
| HY-181714 | EGFR-IN-203 | Inhibitor | / | Unkown |
| HY-144051 | EGFR-IN-34 | Inhibitor | / | Unkown |
| HY-190912 | PKMYT1-IN-18 | Inhibitor | / | Unkown |
| HY-183754 | EGFR-IN-213 | Inhibitor | / | Unkown |
| HY-174231 | EGFR-IN-163 | Inhibitor | / | Unkown |
| HY-147997 | EGFR-IN-68 | Inhibitor | / | Unkown |
| HY-183120 | EGFR T790M/FAK-IN-2 | Inhibitor | / | Unkown |
| HY-146228 | HSP90-IN-13 | Inhibitor | / | Unkown |
| HY-116091 | EGFR-IN-451 | Inhibitor | / | Unkown |
| HY-142519 | EGFR-IN-27 | Inhibitor | / | Unkown |
| HY-159519 | EGFR/HER2-IN-16 | Inhibitor | / | Unkown |
| HY-153557A | HER2-IN-14 | Inhibitor | / | Unkown |
| HY-127067 | Yuanhuadin | Inhibitor | / | Unkown |
| HY-151882 | EGFR-IN-73 | Inhibitor | / | Unkown |
| HY-171443 | Lyso-Monosialoganglioside GM3 | Inhibitor | / | Unkown |
| HY-161145 | EGFR/microtubule-IN-1 | Inhibitor | / | Unkown |
| HY-168559 | EGFR-IN-131 | Inhibitor | / | Unkown |
| HY-157526 | EGFR-TK-IN-1 | Inhibitor | / | Unkown |
| HY-178955 | EGFR-IN-182 | Inhibitor | / | Unkown |
| HY-179098 | Multi-target kinase-IN-8 | Inhibitor | / | Unkown |
| HY-50898S5 | Lapatinib-13C,d7 | Inhibitor | / | Unkown |
| HY-P9905S | 15N-Labeled Cetuximab | / | Unkown | |
| HY-177710 | MEDI4276 | / | Unkown | |
| HY-164056 | EGFR T790M/L858R-IN-8 | Inhibitor | 99.20% | Unkown |
| HY-190642 | CDK2/TrkA-IN-1 | Inhibitor | / | Unkown |
| HY-171884 | BI-8128 | Inhibitor | / | Unkown |
| HY-147802 | EGFR-IN-59 | Inhibitor | / | Unkown |
| HY-182005 | EGFR/VEGFR2-IN-12 | Inhibitor | / | Unkown |
| HY-146422 | PROTAC EGFR degrader 5 | Degrader | / | Unkown |
| HY-P11760 | HER2-targeted peptide H10 | Ligand | / | Unkown |
| HY-175171 | Anticancer agent 276 | Inhibitor | / | Unkown |
| HY-172110 | Apoptosis inducer 35 | Inhibitor | / | Unkown |
| HY-172534 | BPN-01 | Substrate | / | Unkown |
| HY-169408 | EGFR-IN-137 | Inhibitor | / | Unkown |
| HY-175864 | EGFR-IN-173 | Inhibitor | / | Unkown |
| HY-175820 | AGW-11 | Inhibitor | / | Unkown |
| HY-144055 | EGFR-IN-38 | Inhibitor | / | Unkown |
| HY-161030 | EGFR-IN-92 | Inhibitor | / | Unkown |
| HY-175297 | EGFR T790M/VEGFR-2-IN-1 | Inhibitor | / | Unkown |
| HY-155079A | (R)-DZD1516 | Control | 98.80% | Unkown |
| HY-150781 | EGFR-IN-71 | Inhibitor | / | Unkown |
| HY-104080 | HG-5-88-01 | Inhibitor | / | Unkown |
| HY-173314 | EGFR-IN-155 | Inhibitor | / | Unkown |
| HY-169428 | EGFR-IN-138 | / | Unkown | |
| HY-161319 | EGFR-IN-104 | Inhibitor | / | Unkown |
| HY-168469 | EGFR-IN-148 | Inhibitor | / | Unkown |
| HY-13314A | Tesevatinib tosylate | Inhibitor | / | Unkown |
| HY-158154 | EGFR-IN-110 | Inhibitor | / | Unkown |
| HY-170787 | TZEP7 | Inhibitor | / | Unkown |
| HY-116138 | RG-14467 | Inhibitor | / | Unkown |
| HY-151158 | EGFR/HER2-IN-7 | Inhibitor | / | Unkown |
| HY-134470 | PP144 | Inhibitor | / | Unkown |
| HY-190668 | Antitumor agent-234 | Inhibitor | / | Unkown |
| HY-RS04473 | Erbb4 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-149846 | SIQ17 | Inhibitor | / | Unkown |
| HY-32721S | Neratinib-d6 | Inhibitor | 97.04% | Unkown |
| HY-163722 | EGFR/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-189361 | EGFR ligand-19 | Ligand | / | Unkown |
| HY-113549 | Erbstatin | Inhibitor | / | Unkown |
| HY-157398 | EGFR T790M/L858R-IN-3 | Inhibitor | / | Unkown |
| HY-161785 | EGFR-IN-117 | Inhibitor | / | Unkown |
| HY-P11484 | Myosin Regulatory Light Chain MRCL3 (11-24) | / | Unkown | |
| HY-158175 | EGFR T790M/L858R-IN-4 | Inhibitor | / | Unkown |
| HY-163434 | PRMT5/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-143323 | HER2-IN-9 | Inhibitor | / | Unkown |
| HY-172156 | EGFR-TK-IN-5 | Inhibitor | / | Unkown |
| HY-173118 | EGFR-IN-152 | Inhibitor | / | Unkown |
| HY-168623 | EGFR-IN-134 | Inhibitor | / | Unkown |
| HY-RS04210 | Egfr Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-101960 | (Z)-Tyrphostin A51 | Inhibitor | / | Unkown |
| HY-146782 | EGFR-IN-49 | Inhibitor | / | Unkown |
| HY-175173 | EGFR-IN-166 | Inhibitor | / | Unkown |
| HY-151156 | EGFR/HER2-IN-6 | Inhibitor | / | Unkown |
| HY-185276 | EGFR-IN-204 | Inhibitor | 98.57% | Unkown |
| HY-N3634 | Corylifol C | / | Unkown | |
| HY-175531 | EGFR-IN-169 | Inhibitor | / | Unkown |
| HY-P0221A | PACAP (1-38), human, ovine, rat TFA | Inducer | / | Unkown |
| HY-183253 | DL149 | Ligand | / | Unkown |
| HY-172877 | EGFR/BRAFV600E-IN-5 | Inhibitor | / | Unkown |
| HY-RS04471 | Erbb3 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-141486A | PROTAC PARP/EGFR ligand 1 | / | Unkown | |
| HY-181061 | COX/5-LO-IN-2 | Inhibitor | / | Unkown |
| HY-179148 | EGFR-IN-184 | Inhibitor | / | Unkown |
| HY-181829 | Ctx-L3 | Degrader | / | Unkown |
| HY-19730A | Olmutinib hydrochloride | Inhibitor | / | Unkown |
| HY-RS04211 | Egfr Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-172470A | DSPE-PEG3400-GE11 | / | Unkown | |
| HY-189915 | PROTAC EGFR degrader 20 | Degrader | / | Unkown |
| HY-172471 | DSPE-PEG5000-GE11 | / | Unkown | |
| HY-P11613 | DOTA-WC8 | Ligand | / | Unkown |
| HY-173038 | EGFR-IN-151 | Inhibitor | / | Unkown |
| HY-100064S1 | O-Desmethyl gefitinib-d6 | Inhibitor | / | Unkown |
| HY-162148 | HNPMI | Inhibitor | 99.57% | Unkown |
| HY-184719 | VEGFR-2-IN-88 | Inhibitor | / | Unkown |
| HY-173500 | MG-3C | Inhibitor | / | Unkown |
| HY-168073 | EGFR/VEGFR2-IN-1 | Inhibitor | / | Unkown |
| HY-179039 | EGFR-IN-183 | Inhibitor | / | Unkown |
| HY-165394 | Melafolone | Inhibitor | / | Unkown |
| HY-181776 | c-Met-IN-31 | Inhibitor | / | Unkown |
| HY-116059 | EGFR-IN-199 | Inhibitor | / | Unkown |
| HY-144052 | EGFR-IN-35 | Inhibitor | / | Unkown |
| HY-143246 | EGFR kinase inhibitor 1 | Inhibitor | / | Unkown |
| HY-162623 | EGFR/HER2-IN-15 | Inhibitor | / | Unkown |
| HY-RS04467 | Erbb2 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-145844 | EGFR-IN-44 | Inhibitor | / | Unkown |
| HY-178116 | HER2-IN-23 | Inhibitor | / | Unkown |
| HY-172621 | EGFR-IN-159 | Inhibitor | / | Unkown |
| HY-181502 | EGFR-IN-197 | Inhibitor | / | Unkown |
| HY-185833 | ADC Control Human IgG1-JSSW-001 | Inhibitor | / | Unkown |
| HY-177379 | EGFR ligand-14 | / | Unkown | |
| HY-177989 | ER121 | Inhibitor | 98.52% | Unkown |
| HY-149407 | Multi-kinase-IN-4 | Inhibitor | / | Unkown |
| HY-179031 | EGFR/VEGFR2-IN-7 | Inhibitor | / | Unkown |
| HY-163006 | EGFR/c-Met-IN-1 | Inhibitor | / | Unkown |
| HY-50898CS | Lapatinib-d4 tosylate | Inhibitor | / | Unkown |
| HY-131710 | PDE5-IN-3 | Inhibitor | / | Unkown |
| HY-183311 | EGFR-IN-211 | Inhibitor | / | Unkown |
| HY-146132 | EGFR-IN-55 | Inhibitor | / | Unkown |
| HY-155074 | EGFR-IN-79 | Inhibitor | / | Unkown |
| HY-146239 | EGFR/HER2/TS-IN-2 | Inhibitor | / | Unkown |
| HY-163453 | HER2-IN-19 | Inhibitor | / | Unkown |
| HY-189075 | I-0436650 | Inhibitor | / | Unkown |
| HY-147992 | EGFR/HER2-IN-4 | Inhibitor | / | Unkown |
| HY-162099 | VEGFR-IN-4 | Inhibitor | / | Unkown |
| HY-138298B | Trastuzumab deruxtecan (DAR2) | Inhibitor | / | Unkown |
| HY-149695 | EGFR-IN-91 | Inhibitor | / | Unkown |
| HY-144605 | PROTAC EGFR degrader 3 | Inhibitor | 97.39% | Unkown |
| HY-168655 | EGFR/VEGFR2-IN-3 | Inhibitor | / | Unkown |
| HY-169568 | EGFR-IN-147 | Inhibitor | / | Unkown |
| HY-173146 | EGFR-IN-153 | Inhibitor | / | Unkown |
| HY-P12278 | NP1 peptide | Inhibitor | / | Unkown |
| HY-164503 | Neptinib | Inhibitor | / | Unkown |
| HY-P992576 | Anti-EGFR Antibody (425) | Inhibitor | / | Unkown |
| HY-144444 | NSC381467 | Inhibitor | / | Unkown |
| HY-181166 | EGFR-IN-194 | Inhibitor | / | Unkown |
| HY-187838S | Adonertinib | Inhibitor | / | Unkown |
| HY-146423 | PROTAC EGFR degrader 6 | Degrader | / | Unkown |
| HY-173218 | anti-NSCLC agent-1 | Inhibitor | / | Unkown |
| HY-158018 | EGFR-TK-IN-2 | Inhibitor | / | Unkown |
| HY-P0221S | PACAP (1-38), human, ovine, rat-13C5,15N TFA | Inducer | / | Unkown |
| HY-P11757 | Cyclo[K(N3)larllt] | Ligand | / | Unkown |
| HY-161067 | EGFR-IN-96 | Inhibitor | / | Unkown |
| HY-144056 | EGFR-IN-39 | Inhibitor | / | Unkown |
| HY-178448 | EGFR-IN-178 | Inhibitor | / | Unkown |
| HY-168112 | EGFR-IN-127 | Inhibitor | / | Unkown |
| HY-181659 | EGFR-IN-201 | Inhibitor | / | Unkown |
| HY-168427 | Avitinib maleate dihydrate | Inhibitor | / | Unkown |
| HY-182817 | Len-604 | Inhibitor | / | Unkown |
| HY-180922 | EGFR kinase-IN-8 | Inhibitor | / | Unkown |
| HY-159101 | EP26 | Inhibitor | / | Unkown |
| HY-180154 | EGFR/BRAFV600E-IN-6 | Inhibitor | / | Unkown |
| HY-178057 | EGFR-IN-176 | Inhibitor | / | Unkown |
| HY-115933 | EGFR/BRAF-IN-1 | Inhibitor | / | Unkown |
| HY-P5742 | ELAAWCRWGFLLALLPPGIAG | / | Unkown | |
| HY-129288 | GW837016X | Inhibitor | / | Unkown |
| HY-103439A | GW583340 | Inhibitor | / | Unkown |
| HY-179140 | EGFR/VEGFR2-IN-8 | Inhibitor | / | Unkown |
| HY-157912 | EGFR-IN-102 | Inhibitor | / | Unkown |
| HY-188268 | TXX-1-10 | Inhibitor | / | Unkown |
| HY-183090 | EGFR/VEGFR2-IN-13 | Inhibitor | / | Unkown |
| HY-13524A | AG-1478 hydrochloride | Inhibitor | / | Unkown |
| HY-149556 | MTX-241F | Inhibitor | / | Unkown |
| HY-109061A | Lazertinib mesylate hydrate | Inhibitor | / | Unkown |
| HY-161968 | EGFR/PI3Kα-IN-1 | Inhibitor | / | Unkown |
| HY-110328 | PKI-166 hydrochloride | Inhibitor | / | Unkown |
| HY-176938A | iAfaPhos1 | 98.27% | Unkown | |
| HY-160613 | EGFR/HER2-IN-11 | Inhibitor | / | Unkown |
| HY-189877 | EGFR-IN-221 | Inhibitor | / | Unkown |
| HY-189760 | S-023-0996 | Inhibitor | / | Unkown |
| HY-147794 | CDK9-IN-41 | Inhibitor | 98.84% | Unkown |
| HY-145867 | EGFR-IN-45 | Inhibitor | / | Unkown |
| HY-P10792A | HYNIC-H6F | Ligand | / | Unkown |
| HY-185780 | Trastuzumab-DM21 | Inhibitor | / | Unkown |
| HY-163726 | GLUT1/EGFR-IN-1 | Inhibitor | 99.75% | Unkown |
| HY-152019 | EGFR/C797S-IN-1 | Inhibitor | / | Unkown |
| HY-178311 | EGFR Ligand-Linker Conjugates 4 | Ligand | / | Unkown |
| HY-13595R | Chrysophanol (Standard) | Inhibitor | / | Unkown |
| HY-161632 | PROTAC EGFR degrader 10 | Degrader | / | Unkown |
| HY-158969 | EGFR-IN-113 | Inhibitor | / | Unkown |
| HY-100636A | Gefitinib N-oxide hydrochloride | Inhibitor | / | Unkown |
| HY-15990 | CH5164840 | Inhibitor | / | Unkown |
| HY-175608 | EGFR-IN-171 | Inhibitor | / | Unkown |
| HY-175257 | Theophylline-platinum(IV) prodrug-1 | Inhibitor | / | Unkown |
| HY-150905 | EGFR ligand-2 | Inhibitor | / | Unkown |
| HY-187692 | IRAK4-IN-35 | Inhibitor | / | Unkown |
| HY-187334 | EGFR-IN-216 | Inhibitor | / | Unkown |
| HY-P11781 | HW12 | Control | / | Unkown |
| HY-208666 | EGFR-IN-215 | Inhibitor | / | Unkown |
| HY-P10995 | TAT-327 | Inhibitor | / | Unkown |
| HY-143729 | EGFR-IN-29 | Inhibitor | / | Unkown |
| HY-50898S1 | Lapatinib-d7 dihydrochloride | Inhibitor | / | Unkown |
| HY-189725 | EGFR/HER2-IN-21 | Inhibitor | / | Unkown |
| HY-149824 | EGFR T790M/L858R-IN-2 | Inhibitor | 99.66% | Unkown |
| HY-149344 | Anticancer agent 133 | Inhibitor | / | Unkown |
| HY-173619 | EGFR-IN-160 | Inhibitor | / | Unkown |
| HY-143874 | HER2-IN-7 | Inhibitor | / | Unkown |
| HY-135216 | Antiproliferative agent-54 | Inhibitor | / | Unkown |
| HY-161146 | EGFR-IN-100 | Inhibitor | / | Unkown |
| HY-164988 | TX2-120-1 | Degrader | / | Unkown |
| HY-164392 | TAS-121 | Inhibitor | / | Unkown |
| HY-179150 | EGFR-TK-IN-6 | Inhibitor | / | Unkown |
| HY-139884 | EGFR-IN-18 | Inhibitor | / | Unkown |
| HY-157399 | EGFR/HER2-IN-10 | Inhibitor | / | Unkown |
| HY-P10793 | Cyclic(YCDGFYACYMDV) | Inhibitor | / | Unkown |
| HY-168170 | EGFR/VEGFR2-IN-2 | Inhibitor | / | Unkown |
| HY-152144 | EGFR-IN-75 | Inhibitor | / | Unkown |
| HY-169982 | EGFR-IN-136 | Inhibitor | / | Unkown |
| HY-158176 | EGFR T790M/L858R-IN-5 | Inhibitor | / | Unkown |
| HY-181491 | Tubulin-IN-64 | Inhibitor | / | Unkown |
| HY-147798 | EGFR/HER2/CDK9-IN-3 | Inhibitor | / | Unkown |
| HY-118175 | RG 14921 | Inhibitor | / | Unkown |
| HY-163417 | HER2-IN-15 | Inhibitor | / | Unkown |
| HY-155178 | Antiproliferative agent-34 | Inhibitor | / | Unkown |
| HY-174841 | EGFR/HER2-IN-19 | Inhibitor | / | Unkown |
| HY-169308 | EGFR-IN-132 | Inhibitor | / | Unkown |
| HY-116277 | Z118332870 | Inhibitor | / | Unkown |
| HY-189465 | EGFR/STAT3-IN-2 | Inhibitor | / | Unkown |
| HY-156470 | Multi-kinase-IN-6 | Inhibitor | / | Unkown |
| HY-18957B | Lifirafenib maleate | Inhibitor | / | Unkown |
| HY-146154 | EGFR-IN-58 | Inhibitor | / | Unkown |
| HY-153557 | HER2-IN-13 | Inhibitor | / | Unkown |
| HY-137786 | EGFR-IN-16 | Inhibitor | / | Unkown |
| HY-147996 | EGFR-IN-67 | Inhibitor | / | Unkown |
| HY-P9912S | 15N-Labeled Pertuzumab | / | Unkown | |
| HY-172469 | DSPE-PEG1000-GE11 | / | Unkown | |
| HY-147860 | EGFR-IN-61 | Inhibitor | / | Unkown |
| HY-144676 | pan-HER-IN-1 | Inhibitor | / | Unkown |
| HY-RS04474 | Erbb4 Rat Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-162788 | EGFR-IN-121 | Inhibitor | / | Unkown |
| HY-120412 | SKLB188 | Inhibitor | / | Unkown |
| HY-174414 | EGFR/HER2-IN-18 | Inhibitor | / | Unkown |
| HY-190486 | ALK/EGFR-IN-4 | Inhibitor | / | Unkown |
| HY-147994 | EGFR/HER2-IN-5 | Inhibitor | / | Unkown |
| HY-121828 | TX-1123 | Inhibitor | / | Unkown |
| HY-P11590 | WGYRGFYC | Ligand | / | Unkown |
| HY-50898S2 | Lapatinib-d5 | Inhibitor | / | Unkown |
| HY-189399 | EGFR/DNA gyrase B Ligand 1 | / | Unkown | |
| HY-162589 | Lw13 | Inhibitor | 98.26% | Unkown |
| HY-157994 | EGFR WT/T790M-IN-2 | Inhibitor | / | Unkown |
| HY-158988 | EGFR-IN-114 | Inhibitor | / | Unkown |
| HY-162300 | EGFR kinase inhibitor 4 | Inhibitor | / | Unkown |
| HY-181766 | EGFR/VEGFR2-IN-11 | Inhibitor | / | Unkown |
| HY-189291 | EGFR-IN-218 | Inhibitor | / | Unkown |
| HY-173501 | EGFR-IN-157 | Inhibitor | / | Unkown |
| HY-177380 | EGFR ligand-14-PEG3-Boc | / | Unkown | |
| HY-163419 | HER2-IN-18 | Inhibitor | / | Unkown |
| HY-153744 | JGK-068S | Inhibitor | / | Unkown |
| HY-187191 | Autophagy-IN/Ferroptosis inducer-modulator-1 | Inhibitor | / | Unkown |
| HY-114535 | Jaceidin | Inhibitor | / | Unkown |
| HY-147995 | EGFR-IN-64 | Inhibitor | / | Unkown |
| HY-P2548 | pp60 (v-SRC) Autophosphorylation Site, Phosphorylated | / | Unkown | |
| HY-178942 | EGFR/VEGFR2-IN-9 | Inhibitor | / | Unkown |
| HY-175292 | EGFR WT/T790M-IN-3 | Inhibitor | / | Unkown |
| HY-173367 | Anticancer agent 271 | Inhibitor | / | Unkown |
| HY-157432 | EGFR-IN-97 | Inhibitor | / | Unkown |
| HY-151161 | EGFR/HER2-IN-8 | Inhibitor | / | Unkown |
| HY-181479 | EGFR-IN-196 | Inhibitor | / | Unkown |
| HY-178142 | Multi-kinase-IN-7 | Inhibitor | / | Unkown |
| HY-172179 | EGFR/VEGFR2-IN-5 | Inhibitor | / | Unkown |
| HY-146138 | EGFR-IN-57 | Inhibitor | / | Unkown |
| HY-181093 | EGFR-IN-191 | Inhibitor | / | Unkown |
| HY-162881 | DS06652923 | Inhibitor | / | Unkown |
| HY-149401 | EGFR-IN-82 | Inhibitor | / | Unkown |
| HY-159512 | EGFR kinase inhibitor 7 | Inhibitor | / | Unkown |
| HY-160087 | SG3376 | Ligand | / | Unkown |
| HY-178009 | EGFR-IN-175 | Inhibitor | / | Unkown |
| HY-156097 | Anticancer agent 158 | Inhibitor | / | Unkown |
| HY-151377 | RET-IN-19 | Inhibitor | / | Unkown |
| HY-189734 | EGFR/VEGFR2-IN-14 | Inhibitor | / | Unkown |
| HY-163657 | HER2-IN-20 | Inhibitor | / | Unkown |
| HY-162483 | EGFR kinase inhibitor 6 | Inhibitor | / | Unkown |
| HY-171958 | PROTAC EGFR degrader 12 | Degrader | / | Unkown |
| HY-179485 | EGFR/VEGFR2-IN-10 | Inhibitor | / | Unkown |
| HY-180964 | Lys-PEG3-BA | Degrader | / | Unkown |
| HY-112405 | BPIQ-I | Inhibitor | / | Unkown |
| HY-156115 | EGFR/CDK2-IN-3 | Inhibitor | / | Unkown |
| HY-144044 | EGFR-IN-30 | Inhibitor | / | Unkown |
| HY-15772GL | Osimertinib (GMP Like) | Inhibitor | / | Unkown |
| HY-164399 | SST0116CL1 | Degrader | / | Unkown |
| HY-W174279 | Tyrphostin 8 | Inhibitor | 99.10% | Unkown |
| HY-155227S | ALK/EGFR-IN-1-d5 | Inhibitor | / | Unkown |
| HY-170438 | EGFR-IN-139 | / | Unkown | |
| HY-184497 | PROTAC EGFR degrader 18 | Degrader | / | Unkown |
| HY-144053 | EGFR-IN-36 | Inhibitor | / | Unkown |
| HY-142517 | EGFR-IN-25 | Inhibitor | / | Unkown |
| HY-149518 | EGFR/BRAFV600E-IN-3 | Inhibitor | / | Unkown |
| HY-100663 | Gefitinib impurity 2 | 99.56% | Unkown | |
| HY-144054 | EGFR-IN-37 | Inhibitor | / | Unkown |
| HY-158313 | PROTAC EGFR degrader 13 | Inhibitor | / | Unkown |
| HY-181115 | EGFR-IN-193 | Inhibitor | / | Unkown |
| HY-185460 | Pertuzumab-LD3 | Inhibitor | / | Unkown |
| HY-161731 | DS08701581 | Inhibitor | / | Unkown |
| HY-112823S | Almonertinib-d6 | Inhibitor | / | Unkown |
| HY-189846 | ES3-JFTN | Inhibitor | / | Unkown |
| HY-190866 | EGFR/VEGFR-2/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-P12120 | ErbB-2-binding peptide-2 | Ligand | / | Unkown |
| HY-150782 | UNC-CA359 | Inhibitor | / | Unkown |
| HY-163723 | EGFR-IN-116 | Inhibitor | / | Unkown |
| HY-175011 | EGFR-IN-165 | Inhibitor | / | Unkown |
| HY-190462 | EGFPAN_EMBS | Inhibitor | / | Unkown |
| HY-178283 | EGFR-IN-177 | Inhibitor | / | Unkown |
| HY-164490 | LS-106 | Inhibitor | / | Unkown |
| HY-162062 | EGFR WT/T790M/L858R-IN-1 | Inhibitor | / | Unkown |
| HY-138627AR | AST5902 trimesylate (Standard) | Inhibitor | / | Unkown |
| HY-10261AS | Afatinib-d6 dimaleate | Inhibitor | / | Unkown |
| HY-142283CS | N-Methyl-dosimertinib | / | Unkown | |
| HY-118900 | CP-654577 | Inhibitor | / | Unkown |
| HY-137028 | 2′-Thioadenosine | Inhibitor | / | Unkown |
| HY-P11761 | HYNIC-H10F | Ligand | / | Unkown |
| HY-171252 | EGFR-IN-145 | Inhibitor | / | Unkown |
| HY-145823 | EGFR-IN-42 | Inhibitor | / | Unkown |
| HY-15268 | PP487 | Inhibitor | / | Unkown |
| HY-N1988R | Cucurbitacin IIa (Standard) | Inhibitor | / | Unkown |
| HY-189464 | EGFR/Akt/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-172160 | HER2-IN-21 | Inhibitor | / | Unkown |
| HY-184274 | EGFR/c-SRC-IN-1 | Inhibitor | / | Unkown |
| HY-161602 | EGFR/HER2-IN-13 | Inhibitor | / | Unkown |
| HY-P5742A | ELAAWCRWGFLLALLPPGIAG TFA | / | Unkown | |
| HY-143901 | EGFR-IN-40 | Inhibitor | / | Unkown |
| HY-170559 | EGFR-IN-141 | Inhibitor | / | Unkown |
| HY-178005 | EGFR-IN-174 | Inhibitor | / | Unkown |
| HY-163632 | EGFR-IN-112 | Inhibitor | / | Unkown |
| HY-146471 | EGFR-IN-51 | Inhibitor | / | Unkown |
| HY-161923 | EGFR-IN-120 | Inhibitor | / | Unkown |
| HY-162360 | EGFR-IN-109 | Inhibitor | / | Unkown |
| HY-172966 | EG31 | Inhibitor | / | Unkown |
| HY-173164 | EGFR/BRAFV600E-IN-4 | Inhibitor | / | Unkown |
| HY-151981 | EGFR-IN-74 | Inhibitor | / | Unkown |
| HY-175220 | 4-TCPA | Inhibitor | / | Unkown |
| HY-114253 | ODS-2004436 | / | Unkown | |
| HY-161866 | EGFR-IN-118 | Inhibitor | / | Unkown |
| HY-172780 | EGFR-IN-161 | Inhibitor | / | Unkown |
| HY-172897 | EGFR/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-160564 | ZNL-0056 | Inhibitor | / | Unkown |
| HY-10261E | (R)-Afatinib | Inhibitor | / | Unkown |
| HY-146473 | EGFR-IN-53 | Inhibitor | / | Unkown |
| HY-179049 | EGFR/tubulin-IN-1 | Inhibitor | / | Unkown |
| HY-142678 | EGFR-IN-21 | Inhibitor | / | Unkown |
| HY-P11944 | Peptide 22 | Chemical | / | Unkown |
| HY-149632 | EGFR/HER2/DHFR-IN-2 | Inhibitor | / | Unkown |
| HY-156457 | EGFR-IN-90 | Inhibitor | / | Unkown |
| HY-168492 | TrxR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-168876 | AZ14240475 | Inhibitor | / | Unkown |
| HY-189360 | PROTAC EGFR degrader 19 | Degrader | / | Unkown |
| HY-151154 | EGFR/HER2/DHFR-IN-1 | Inhibitor | / | Unkown |
| HY-152852S | Mefatinib-d6 free base | Inhibitor | / | Unkown |
| HY-163420 | HER2-IN-16 | Inhibitor | / | Unkown |
| HY-160682 | EGFR/HER2-IN-12 | Inhibitor | / | Unkown |
| HY-172091 | CZY43 | Degrader | / | Unkown |
| HY-146325 | HSP90-IN-11 | Degrader | / | Unkown |
| HY-185227 | EphB4-IN-1 | Inhibitor | / | Unkown |
| HY-150908 | Brigatinib A | Ligand | / | Unkown |
| HY-169427 | FRF-06-057 | Inhibitor | / | Unkown |
| HY-176556 | EGFR-IN-167 | Inhibitor | / | Unkown |
| HY-147967 | EGFR-IN-63 | Inhibitor | / | Unkown |
| HY-138746 | EGFR-IN-15 | Inhibitor | 96.21% | Unkown |
| HY-184311 | EGFR-IN-214 | Inhibitor | / | Unkown |
| HY-402309 | IGF-1R modulator 1 | Modulator | 99.75% | Unkown |
| HY-172111 | EGFR-IN-144 | Inhibitor | / | Unkown |
| HY-147826 | EGFR-IN-60 | Inhibitor | / | Unkown |
| HY-182264 | Masoprocol tetrapivalate | Inhibitor | / | Unkown |
| HY-133453 | PROTAC EGFR degrader 1 | Degrader | / | Unkown |
| HY-142679 | EGFR-IN-22 | Inhibitor | / | Unkown |
| HY-P10648 | Herceptide | / | Unkown | |
| HY-149275 | PKM2/PDK1-IN-1 | Inhibitor | / | Unkown |
| HY-175805 | EGFR/HDAC-IN-2 | Inhibitor | / | Unkown |
| HY-178353 | EGFR/Cytokine-IN-1 | Inhibitor | / | Unkown |
| HY-103630 | PROTAC Her3 Degrader-2 | Degrader | / | Unkown |
| HY-179522 | EGFR-IN-186 | Inhibitor | / | Unkown |
| HY-182031 | JS04 | Inhibitor | / | Unkown |
| HY-163000 | EGFR-IN-129 | Inhibitor | / | Unkown |
| HY-170543 | Dual Galectin-3/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-176938 | AfaPhos1 | Inhibitor | / | Unkown |
| HY-151573 | EGFR/CDK2-IN-1 | Inhibitor | / | Unkown |
| HY-182742 | EGFR-IN-208 | Inhibitor | / | Unkown |
| HY-N6678S | (Rac)-Zearalanone-d6 | Degrader | / | Unkown |
| HY-168627 | EGFR-IN-135 | Inhibitor | / | Unkown |
| HY-170665 | EGFR T790M/L858R-IN-9 | Inhibitor | / | Unkown |
| HY-180242 | EGFR/CDK2-IN-5 | Inhibitor | / | Unkown |
| HY-164489 | KU004 | Inhibitor | / | Unkown |
| HY-P11890 | GPVGPS | Modulator | / | Unkown |
| HY-P1828 | EGFRvIII peptide (PEPvIII) | / | Unkown | |
| HY-146210 | EGFR-IN-50 | Inhibitor | / | Unkown |
| HY-123891 | NS-062 | Inhibitor | / | Unkown |
| HY-178442 | EGFR-IN-179 | Inhibitor | / | Unkown |
| HY-183310 | EGFR-IN-210 | Inhibitor | / | Unkown |
| HY-169346 | Pred17 | Inhibitor | / | Unkown |
| HY-15772G | Osimertinib (GMP) | Inhibitor | / | Unkown |
| HY-178440 | EGFR/COX-2-IN-2 | Inhibitor | / | Unkown |
| HY-112334 | EGFR-IN-198 | Inhibitor | 99.57% | Unkown |
| HY-181099 | EGFR WT/T790M-IN-4 | Inhibitor | / | Unkown |
| HY-100636 | Gefitinib N-oxide | Inhibitor | / | Unkown |
| HY-147796 | EGFR/HER2/CDK9-IN-1 | Inhibitor | / | Unkown |
| HY-149633 | EGFR/HER2/DHFR-IN-3 | Inhibitor | / | Unkown |
| HY-145824 | EGFR-IN-43 | Inhibitor | / | Unkown |
| HY-175635 | EGFR/VEGFR2-IN-6 | Inhibitor | / | Unkown |
| HY-RS04469 | ERBB3 Human Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-181056 | EGFR/COX-2-IN-3 | Inhibitor | 99.76% | Unkown |
| HY-146136 | EGFR-IN-56 | Inhibitor | / | Unkown |
| HY-179529 | EGFR/InhA-IN-1 | Inhibitor | / | Unkown |
| HY-178939 | EGFR-IN-181 | Inhibitor | / | Unkown |
| HY-144445 | NSC114126 | Inhibitor | / | Unkown |
| HY-170968 | EGFR-IN-150 | Inhibitor | / | Unkown |
| HY-161045 | T-1-DOCA | Inhibitor | / | Unkown |
| HY-RS04470 | Erbb3 Mouse Pre-designed siRNA Set A | Inhibitor | / | Unkown |
| HY-181097 | EGFR-IN-192 | Inhibitor | / | Unkown |
| HY-174415 | ZSH-2117 | Degrader | / | Unkown |
| HY-158153 | EGFR-IN-108 | Inhibitor | / | Unkown |
| HY-10261S1 | Afatinib-d4 | Inhibitor | / | Unkown |
| HY-172623 | EGFR/HER2-IN-17 | Inhibitor | / | Unkown |
| HY-163418 | HER2-IN-17 | Inhibitor | / | Unkown |
| HY-181701 | EGFR-IN-202 | Inhibitor | / | Unkown |
| HY-147825 | EGFR/BRAFV600E-IN-1 | Inhibitor | / | Unkown |
| HY-146238 | EGFR/HER2/TS-IN-1 | Inhibitor | / | Unkown |
| HY-B0793GL | AZ-5104 (GMP Like) | Inhibitor | / | Unkown |
| HY-169216 | Multi-target kinase inhibitor 3 | Inhibitor | / | Unkown |
| HY-161031 | EGFR-IN-93 | Inhibitor | / | Unkown |
| HY-103629 | PROTAC Her3 Degrader-1 | Inhibitor | / | Unkown |
| HY-100064S | O-Desmethyl gefitinib-d8 | Inhibitor | 99.84% | Unkown |
| HY-178824 | EGFR-IN-180 | Inhibitor | / | Unkown |
| HY-172795 | EGFR-IN-158 | Inhibitor | / | Unkown |
| HY-189142 | EGFR-IN-217 | Inhibitor | / | Unkown |
| HY-50898S3 | Lapatinib-d4-1 | Inhibitor | / | Unkown |
| HY-117852 | CGP-59326 | Inhibitor | / | Unkown |
| HY-183292 | SH-1092 | Inhibitor | / | Unkown |
| HY-180965 | Pro-PEG3-BA | Degrader | / | Unkown |
| HY-184116 | A2AR/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-167948 | Dacomitinib metabolite M1/2 | Inhibitor | / | Unkown |
| HY-169309 | EGFR-IN-133 | Inhibitor | / | Unkown |
| HY-P11078 | LARLLT | / | Unkown | |
| HY-170932 | EGFR/COX-2-IN-1 | Inhibitor | / | Unkown |
| HY-151049 | EGFR ligand-8 | Ligand | / | Unkown |
| HY-144794 | EGFR-IN-46 | Inhibitor | / | Unkown |
| HY-175837 | EGFR-IN-172 | Inhibitor | / | Unkown |
| HY-178119 | HER4/HER2-IN-1 | Inhibitor | / | Unkown |
| HY-162964 | EGFR-IN-126 | Inhibitor | / | Unkown |
| HY-189146 | HDTAC EGFR Degrader-1 | Degrader | / | Unkown |
| HY-144760 | EGFR-IN-3 | Inducer | / | Unkown |
| HY-P10569 | Biotin HER-2 substrate peptide | / | Unkown | |
| HY-P10686 | CH401 peptide | / | Unkown | |
| HY-146474 | EGFR-IN-54 | Inhibitor | / | Unkown |
| HY-10368 | EGFR/VEGFR2-IN-4 | Inhibitor | / | Unkown |
| HY-190903 | YNW-1 | Inhibitor | / | Unkown |
| HY-178242 | PROTAC EGFR degrader 16 | Degrader | / | Unkown |
| HY-W777297 | Lapatinib-13C2,15N Ditosylate | / | Unkown | |
| HY-P11752 | Cyclo(KLARLLT) | Ligand | / | Unkown |
| HY-183277 | EGFR-IN-209 | Inhibitor | / | Unkown |
| HY-163402 | EGFR-IN-108 chloride | Inhibitor | / | Unkown |
| HY-163377 | AZ5385 | Inhibitor | / | Unkown |
| HY-120857 | BPIQ-II hydrochloride | Inhibitor | / | Unkown |
| HY-P990049A | Becotatug (powder) | Inhibitor | / | Unkown |
| HY-177270 | CHNQD-01281 | Modulator | / | Unkown |
| HY-13272S3 | Dacomitinib-d10 | Inhibitor | / | Unkown |
| HY-179600 | Dyrk1A-IN-16 | Inhibitor | / | Unkown |
| HY-181657 | EGFR-IN-200 | Inhibitor | / | Unkown |
| HY-170497 | EGFR-IN-140 | Inhibitor | / | Unkown |
| HY-N16557 | (Rac)-8-Gingerol | Inhibitor | / | Unkown |
| HY-180823 | Topoisomerase II/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-189466 | EGFR-IN-219 | Inhibitor | / | Unkown |
| HY-103437 | EGFR-IN-80 | Inhibitor | / | Unkown |
| HY-179599 | Dyrk1A-IN-15 | Inhibitor | / | Unkown |
| HY-18957A | rel-Lifirafenib | Control | / | Unkown |
| HY-168151 | EGFR-IN-128 | Inhibitor | / | Unkown |
| HY-180949 | EGFR-IN-189 | Inhibitor | / | Unkown |
| HY-18298 | PD 173955 analog 1 | Inhibitor | / | Unkown |
| HY-161136 | EGFR/STAT3-IN-1 | Inhibitor | / | Unkown |
| HY-180541 | EGFR-IN-190 | Inhibitor | / | Unkown |
| HY-144050 | EGFR-IN-33 | Inhibitor | / | Unkown |
| HY-B0793G | AZ-5104 (GMP) | Inhibitor | / | Unkown |
| HY-172104 | EGFR-IN-143 | Inhibitor | / | Unkown |
| HY-P10224 | G7-18NATE | / | Unkown | |
| HY-182064 | EGFR-IN-206 | Inhibitor | / | Unkown |
| HY-177009 | Tucatinib analog B | Ligand | / | Unkown |
| HY-163880 | EGFR-IN-119 | Inhibitor | / | Unkown |
| HY-156991 | NODAGA-NHS | / | Unkown | |
| HY-P10994 | Eps8 peptide 327 | Inhibitor | / | Unkown |
| HY-183788 | EGFR-IN-212 | Inhibitor | / | Unkown |
| HY-N9684 | Degalactotigonin | Inhibitor | / | Unkown |
| HY-179143 | EGFR-IN-185 | Inhibitor | / | Unkown |
| HY-138298D | Trastuzumab deruxtecan (DAR6) | Inhibitor | 95.25% | Unkown |
| HY-173188 | EGFR-IN-154 | Inhibitor | / | Unkown |
| HY-W008914 | (E/Z)-CP-724714 | Inhibitor | / | Unkown |
| HY-W706930 | DCBA-d10 | / | Unkown | |
| HY-170661 | EGFR-IN-142 | Inhibitor | / | Unkown |
| HY-168433 | LSD1/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-144097 | HER2-IN-8 | Inhibitor | / | Unkown |
| HY-158016 | Antiproliferative agent-49 | Inhibitor | / | Unkown |
| HY-155200 | EGFR-IN-84 | Inhibitor | / | Unkown |
| HY-P10659 | Self-assembling peptide pY1 | / | Unkown | |
| HY-157402 | Topoisomerase II/EGFR-IN-1 | / | Unkown | |
| HY-147797 | EGFR/HER2/CDK9-IN-2 | Inhibitor | / | Unkown |
| HY-115952 | EGFR/HER2-IN-3 | Inhibitor | / | Unkown |
| HY-176744 | HER2-IN-22 | Inhibitor | / | Unkown |
| HY-10188 | SKS-927 | Inhibitor | / | Unkown |
| HY-189638 | Antiproliferative agent-84 | Inhibitor | / | Unkown |
| HY-156033 | EGFR-IN-88 | Inhibitor | / | Unkown |
| HY-184720 | VEGFR-2-IN-89 | Inhibitor | / | Unkown |
| HY-158177 | EGFR T790M/L858R-IN-6 | Inhibitor | / | Unkown |
| HY-144441 | NSC81111 | Inhibitor | / | Unkown |
| HY-W409652 | CLK1/4-IN-2 | Inhibitor | / | Unkown |
| HY-147862 | EGFR-IN-62 | Inhibitor | / | Unkown |
| HY-142680 | EGFR-IN-23 | Inhibitor | / | Unkown |
| HY-173520 | EGFR/HDAC-IN-1 | Inhibitor | / | Unkown |
| HY-175809 | SRT6 | Inhibitor | 99.90% | Unkown |
| HY-138627B | AST5902 mesylate | Inhibitor | / | Unkown |
| HY-172961 | EGFR-IN-162 | Inhibitor | / | Unkown |
| HY-181142 | Antitumor agent-213 | / | Unkown | |
| HY-147248 | Opadotina | Inhibitor | / | Unkown |
| HY-181251 | EGFR-IN-195 | Inhibitor | / | Unkown |
| HY-162332 | EGFR-PK/JNK-2-IN-1 | Inhibitor | / | Unkown |
| HY-162891 | EGFR-IN-123 | Inhibitor | / | Unkown |
| HY-160828 | O-Desmethyl dacomitinib | Inhibitor | / | Unkown |
| HY-184301 | EGFR/HER2-IN-20 | Inhibitor | / | Unkown |
| HY-187517 | Anticancer agent 357 | Inhibitor | / | Unkown |
| HY-181923 | IMP-Zn | / | Unkown | |
| HY-162323 | EGFR-IN-106 | Inhibitor | / | Unkown |
| HY-163371 | EGFR WT/T790M-IN-1 | Inhibitor | / | Unkown |
| HY-178313 | EGFR ligand-18 | Degrader | / | Unkown |
| HY-168514 | SOS1/EGFR-IN-2 | Inhibitor | / | Unkown |
| HY-143445 | EGFR-IN-48 | Inhibitor | / | Unkown |
| HY-175316 | EGFR-IN-168 | Inhibitor | / | Unkown |
| HY-168173 | EGFR-IN-130 | Inhibitor | / | Unkown |
| HY-147741 | DPPY | Inhibitor | / | Unkown |
| HY-180536 | HB-EGF-IN-1 | Inhibitor | / | Unkown |
| HY-168064 | EGFR-IN-124 | Inhibitor | / | Unkown |
| HY-18213 | EGFR-IN-9 | Inhibitor | 98.69% | Unkown |
| HY-P1085 | Epidermal Growth Factor Receptor Peptide (985-996) | Chemical | / | Unkown |
| HY-153605 | EGFR-IN-77 | Inhibitor | / | Unkown |
| HY-157166 | EGFR kinase inhibitor 2 | Inhibitor | / | Unkown |
| HY-183373 | EGFR/PARP-1-IN-1 | Inhibitor | / | Unkown |
| HY-161269 | EGFR-IN-101 | Inhibitor | / | Unkown |
| HY-180966 | Gly-PEG3-BA | Degrader | / | Unkown |
| HY-182073 | EGFR-IN-207 | Inhibitor | / | Unkown |
| HY-164413 | CLM3 | Inhibitor | / | Unkown |
| HY-163860 | EGFR-TK-IN-3 | Inhibitor | / | Unkown |
| HY-101959 | Tyrphostin AG213 | Inhibitor | / | Unkown |
| HY-175009 | MRC-G-001 | Inhibitor | / | Unkown |
| HY-155227 | ALK/EGFR-IN-1 | Inhibitor | / | Unkown |
| HY-156114 | EGFR/CDK2-IN-2 | Inhibitor | / | Unkown |
| HY-174826 | EGFR-IN-164 | Inhibitor | / | Unkown |
| HY-151162 | HER2-IN-12 | Inhibitor | / | Unkown |
| HY-183123 | EGFR T790M/FAK-IN-1 | Inhibitor | / | Unkown |
| HY-103566A | LY456236 free base | Inhibitor | / | Unkown |
| HY-149517 | EGFR/BRAFV600E-IN-2 | Inhibitor | / | Unkown |
| HY-187533 | EGFR AUTOTAC-1 | Degrader | / | Unkown |
| HY-P5745A | TYVPANASL TFA | / | Unkown | |
| HY-N14635 | Paeciloquinone A | Inhibitor | / | Unkown |
| HY-14674A | CP-724714 succinate | Inhibitor | / | Unkown |
| HY-184315 | LDC8201 | Inhibitor | / | Unkown |
| HY-111072 | ADS103317 | / | Unkown | |
| HY-111300 | G3130 | Degrader | / | Unkown |
| HY-50896S2 | Erlotinib-d4 | Inhibitor | / | Unkown |
| HY-116068 | DW532 | Inhibitor | / | Unkown |
| HY-111250 | SYR127063 | Inhibitor | / | Unkown |
| HY-118032 | Bozepinib | Inhibitor | / | Unkown |
| HY-135727 | PF-6422899 | Inhibitor | / | Unkown |
| HY-183377 | DMBT | Inhibitor | / | Unkown |
| HY-156487 | CNBDA | Inhibitor | / | Unkown |
| HY-50898S4 | Lapatinib-d7 | Inhibitor | / | Unkown |
| HY-183400 | BIM-46174 | Inhibitor | / | Unkown |
| HY-124633 | NEU-1953 | Inhibitor | / | Unkown |
| HY-158829A | SSOe26 sodium scrambled negative control | / | Unkown | |
| HY-137081 | AKOS024836912 | Inhibitor | / | Unkown |
| HY-15769A | WHI-P180 hydrochloride | Inhibitor | / | Unkown |
| HY-15495B | (3S)-Tanzisertib hydrochloride | Inhibitor | / | Unkown |
| HY-169566 | EGFR-IN-146 | Inhibitor | / | Unkown |
| HY-158829 | SSOe26 sodium | / | Unkown | |
| HY-153887 | HyT36(-Cl) | Control | / | Unkown |
| HY-159047 | EGFR ligand-10 | Degrader | / | Unkown |
| HY-178740 | GI261520A | Inhibitor | / | Unkown |
| HY-190490 | PAK4-IN-8 | Inhibitor | / | Unkown |
| HY-169948 | BML-265 | Inhibitor | / | Unkown |
| HY-N14639 | Paeciloquinone E | Inhibitor | / | Unkown |
| HY-158828 | SSO111 sodium | / | Unkown | |
| HY-117523 | (Z)-RG-13022 | Inhibitor | / | Unkown |
| HY-W259575 | CDKi free base | Inhibitor | / | Unkown |
| HY-103443A | HKI-357 dimaleate | Inhibitor | / | Unkown |
| HY-100742R | GNE-140 racemate (Standard) | Inhibitor | / | Unkown |
| HY-N14638 | Paeciloquinone D | Inhibitor | / | Unkown |
| HY-114667 | Lavendustin C6 | Inhibitor | / | Unkown |
| HY-135725 | D-69491 hydrochloride | Inhibitor | / | Unkown |
| HY-169755 | Tyrphostin 63 | Inhibitor | / | Unkown |
| HY-164527 | Si306 | Inhibitor | / | Unkown |
| HY-169570 | EGFR-IN-149 | Inhibitor | / | Unkown |
| HY-180498 | NSC 57148 | Inhibitor | / | Unkown |
| HY-10325R | CL-387785 (Standard) | Inhibitor | / | Unkown |
| HY-32718S | Pelitinib-d6 | / | Unkown | |
| HY-180325 | DDC4002 | Inhibitor | / | Unkown |
| HY-110045 | ZM-306416 hydrochloride | Inhibitor | / | Unkown |
| HY-10263 | BMS-554417 | Activator | / | Unkown |
| HY-117252 | HS-72 | / | Unkown | |
| HY-158828A | SSO111 sodium scrambled negative control | / | Unkown | |
| HY-168305 | EGFR ligand-11 | / | Unkown | |
| HY-180480 | NSC 104999 | Ligand | / | Unkown |
| HY-N14636 | Paeciloquinone B | Inhibitor | / | Unkown |
| HY-160068 | 2-2(t) aptamer sodium | Chemical | 99.28% | Unkown |
| HY-163396 | EGFR-IN-107 | Inhibitor | / | Unkown |
| HY-183402 | FLLL12 | Inhibitor | / | Unkown |
| HY-19909A | NRC-2694-A | Inhibitor | / | Unkown |
| HY-N20729 | Eucommin A | Modulator | / | Unkown |
| HY-W740378 | 1,2,3,4-Tetrahydro Staurosporin | Inhibitor | / | Unkown |
| HY-N14637 | Paeciloquinone C | Inhibitor | / | Unkown |
| HY-16069S | Tucatinib-d6 | Inhibitor | / | Unkown |
| HY-50896S3 | Erlotinib-d8 | Inhibitor | / | Unkown |
| HY-12000R | AG490 (Standard) | Inhibitor | / | Unkown |
| HY-183456 | Tyrphostin AG17 | Inhibitor | / | Unkown |
| HY-183397 | Avitinib dihydrochloride | Inhibitor | / | Unkown |
| HY-146262 | LDC0496 | Inhibitor | / | Unkown |
| Cat. No. | Nom du produit |
Effect
|
Pureté |
Rare Diseases
|
|---|---|---|---|---|
| HY-P9907A | Trastuzumab (anti-HER2) | Inhibitor | 99.838% | Unkown |
| HY-P9S0008 | Cetuximab (PBS) | Inhibitor | 99.33% | Unkown |
| HY-P99854 | Disitamab | Inhibitor | 98.73% | Unkown |
| HY-P9912A | Pertuzumab (anti-HER2) | Inhibitor | 99.10% | Unkown |
| HY-P990947 | Tilatamig | Inhibitor | 99.99% | Unkown |
| HY-P99684 | Laprituximab | Inhibitor | 99.74% | Unkown |
| HY-P990238 | Anti-Human/Rat HER2 (neu) Antibody (7.16.4) | Inhibitor | 95.00% | Unkown |
| HY-P9977A | Amivantamab (FUT8-KO) | Inhibitor | 99.00% | Unkown |
| HY-P99892 | Serclutamab | 99.97% | Unkown | |
| HY-P99324 | Tomuzotuximab | Inhibitor | ≥99.0% | Unkown |
| HY-P99406A | Petosemtamab (FUT8-KO) | Degrader | 99% | Unkown |
| HY-P99715 | Losatuxizumab | Inhibitor | 99.44% | Unkown |
| HY-P99558 | Timigutuzumab | Inhibitor | 97.53% | Unkown |
| HY-P990962 | Vislarafusp alfa | 98.98% | Unkown | |
| HY-P99888 | Pimurutamab | 99.42% | Unkown | |
| HY-P990909 | Calotatug | 98% | Unkown | |
| HY-P990978 | Caxmotabart | 96.56% | Unkown | |
| HY-P992137 | Turigrobart | Inhibitor | 99.9% | Unkown |
| HY-P991505 | Anti-HER3 Antibody (Ab562) | Antagonist | 99.63% | Unkown |
| HY-P991780 | Anti-Mouse HER2 (domain I) Antibody (H2Mab-304) | Inhibitor | 97.589% | Unkown |
| HY-P990972 | Azerutamig | / | Unkown | |
| HY-P991779 | Anti-Mouse/Human/Canine HER2 (domain III) Antibody (H2Mab-19) | Inhibitor | 99.05% | Unkown |
| HY-P991966 | Anti-Human/Mouse EGFR Antibody (7A7) | 99.45% | Unkown | |
| HY-P992107 | Dulpatatug | Inhibitor | 99.09% | Unkown |
| HY-P991159 | Ruzaltatug | Inhibitor | 95.69% | Unkown |
| HY-P992140 | Varzutamig | Inhibitor | / | Unkown |
| HY-P99295A | Imgatuzumab (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P992401 | M802 | Inhibitor | / | Unkown |
| HY-P991970 | REGN3124 | Inhibitor | / | Unkown |
| HY-P991783 | Anti-Mouse EGFR (domain I) Antibody (EMab-300) | Inhibitor | / | Unkown |
| HY-P990248 | Anti-Mouse E-Cadherin/CD324 Antibody (DECMA-1) | Inhibitor | 98.53% | Unkown |
| HY-P991977 | BSI-001 | Inhibitor | / | Unkown |
| HY-P990408 | Anti-ERBB1/EGFR/HER1 Antibody | Inhibitor | / | Unkown |
| HY-P991969 | LR004 | Inhibitor | / | Unkown |
| HY-P991092A | IBI-334 (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991239 | NM-02 | Inhibitor | / | Unkown |
| HY-P991573 | Anti-EGFR Antibody (D2C7) | Inhibitor | / | Unkown |
| HY-P991241 | Anti-ERBB3/HER3 (29Z6) | Inhibitor | / | Unkown |
| HY-P991234 | COVA208 | Degrader | / | Unkown |
| HY-P991980 | H2Mab-139 | Inhibitor | / | Unkown |
| HY-P990755A | Pamvatamig (FUT8-KO) | Inhibitor | / | Unkown |
| HY-P991245 | Anti-ERBB3/HER3 (SGP1) | Inhibitor | / | Unkown |
| HY-P991986 | Anti-Epiregulin Antibody | Inhibitor | / | Unkown |
| HY-P991243 | MP-RM-1 | Inhibitor | 96.29% | Unkown |
| HY-P9968A | Nimotuzumab (powder) | Inhibitor | / | Unkown |
| HY-P991236 | MHES0488A | Inhibitor | 95.83% | Unkown |
| HY-P991784 | Anti-Mouse/Human EGFR (domain III) Antibody (EMab-88) | Inhibitor | / | Unkown |
| HY-P992171 | ADCT-701 Antibody | / | Unkown | |
| HY-P991967 | AVID100 Antibody | Inhibitor | / | Unkown |
| HY-P991968 | HTI-1511 Antibody | Inhibitor | / | Unkown |
| HY-P991985 | Anti-Her4 Antibody | Inhibitor | / | Unkown |
| HY-P991979 | Erbicin | Inhibitor | / | Unkown |